

10/554, 254
EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	531	(544/251,544/252,514/267).CCLS.	US-PGPUB; USPAT	OR	OFF	2007/07/02 15:23
L2	531	(544/251,544/252,514/267, 540/560,540/562,540/469, 540/559).CCLS.	US-PGPUB; USPAT	OR	OFF	2007/07/02 15:25
L3	0	I1 and tricyclid adj pyrimidine	US-PGPUB; USPAT	OR	ON	2007/07/02 15:26
L4	2	I1 and tricyclic adj pyrimidine	US-PGPUB; USPAT	OR	ON	2007/07/02 15:26

10/SS4,2ST

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEAL1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 MAR 12 Web Page for STN-Seminar Schedule - N. America
NEWS 2 MAR 12 WINSOS/WPL1 enhanced with new FRAGHITSTR display format
NEWS 3 MAR 16 CASPLUS coverage extended
NEWS 4 MAR 20 MARPAT now updated daily
NEWS 5 MAR 22 LNP1 reloaded
NEWS 6 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 7 APR 02 JICST-EPLUS removed from database clusters and STN
NEWS 8 APR 10 GRNBANK reloaded and enhanced with Genome Project ID field
NEWS 9 APR 10 CHEMCATS enhanced with 1.2 million new records
NEWS 10 APR 10 CA/Caplus enhanced with 1870-1889 U.S. patent records
NEWS 11 APR 10 INPADOC replaced by INPADOCDB on STN
NEWS 12 MAY 01 New CAS web site launched
NEWS 13 MAY 08 CA/Caplus Indian patent publication number format defined
NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 16 MAY 21 TOX CENTER enhanced with BIOSIS reload
NEWS 17 MAY 21 CA/Caplus enhanced with additional kind codes for German patents
NEWS 18 MAY 22 CA/Caplus enhanced with IPC reclassification in Japanese patents
NEWS 19 JUN 27 CA/Caplus enhanced with pre-1967 CAS Registry Numbers
NEWS 20 JUN 29 STN viewer, now available
NEWS 21 JUN 29 STN Express, Version 4.2, now available
NEWS 22 JUL 02 LNBASB coverage updated
NEWS 23 JUL 02 LMBDLINE coverage updated
NEWS 24 JUL 02 SCISEARCH enhanced with complete author names
NEWS 25 JUL 02 CHEMCATS accession numbers revised
NEWS 26 JUL 02 CA/Caplus enhanced with utility model patents from China

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(EN) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 4 MAY 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer Agreement. Please note that this agreement limits use to scientific


<12/04/2007>

Erich Leese

<12/04/2007>

Erich Leese

10/513699



G1 C,N
G2 H,Cy,Ak

STRUCTURE ATTRIBUTES must be viewed using STN Express query preparation.

> s 11
SAMPLE SEARCH INITIATED 17:24:52 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1539 TO ITERATE

100.0% PROCESSED 1539 ITERATIONS 30 ANSWERS
SEARCH TIME: 00:00:01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 28427 TO 33133
PROJECTED ANSWERS: 272 TO 928

L2 30 SEA SSS BAM L1

> s 11 full
FULL SEARCH INITIATED 17:24:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 31457 TO ITERATE

100.0% PROCESSED 31457 ITERATIONS 538 ANSWERS
SEARCH TIME: 00:00:02

L3 538 SEA SSS FUL L1

> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
172.55 172.76
FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 17:25:01 ON 02 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

10/513699

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****
FILE 'HOME' ENTERED AT 17:23:34 ON 02 JUL 2007
> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL
0.21 0.21
FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 17:23:59 ON 02 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITY data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 JUL 2007 HIGHEST RN 940612-32-8
DICTIONARY FILE UPDATES: 1 JUL 2007 HIGHEST RN 940612-32-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006
Please note that search-term pricing does apply when
conducting SMARTSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

>>
Uploading C:\Program Files\Stnexp\Queries\10554254.str
L1 STRUCTURE UPLOADED
>> d 11
L1 HAS NO ANSWERS
L1 STR

10/513699

Copyright of the articles to which records in this database refer is held by the publisher listed in the PUBLISHER (PS) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Jul 2007 VOL 147 ISS 2
FILE LAST UPDATED: 1 Jul 2007 (20070701/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

>> s 13 full
L4 46 L3
>> d ibib abs hitarr tot

L4 ANSWER 1 OF 46 CAPLUS COPYRIGHT 2007 ACS ON STN
ACCESSION NUMBER: 2007:245614 CAPLUS

DOCUMENT NUMBER: 145:454155

TITLE: 3D-Pharmacophore Models for Selective A2A and A2B

Adenosine Receptor Antagonists

AUTHOR(S): Wei, Jing; Wang, Songqing; Gao, Shaofen; Dai, Xuedong; Gao, qingzhi

CORPORATE SOURCE: School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, 300072, Peop. Rep. China

SOURCE: Journal of Chemical Information and Modeling (2007), 47(2), 613-625

PUBLISHER: CODEN: JCISD8, ISSN: 1549-9596

DOCUMENT TYPE: American Chemical Society

LANGUAGE: English

AB These dimensional pharmacophore models were generated for A2A and A2B adenosine receptors (A2s) based on highly selective A2A and A2B antagonists using the Catalyst program. The best pharmacophore model for selective A2A antagonists (Hypo-A2A) was obtained through a careful validation process. Four features contained in Hypo-A2A (one ring aromatic feature (R), one pos. ionizable feature (P), one hydrogen bond acceptor lipid feature (L), and one hydrophobic feature (H)) seem to be essential for antagonists in terms of binding activity and A2A AR selectivity. The best pharmacophore model for selective A2B antagonists (Hypo-A2B) was elaborated by modifying the Catalyst common features (HipHop) hypotheses generated from the selective A2B antagonists training set. Hypo-A2B also consists of four features: one ring aromatic feature (R), one hydrophobic aliphatic feature (Z), and two hydrogen bond acceptor lipid features (L). All features play an important role in A2B AR binding affinity and are essential for A2B selectivity. Both A2A and A2B pharmacophore models have been validated toward a wide set of test molecules containing structurally diverse selective antagonists of all A2 subtypes. They are capable of identifying correspondingly high potent antagonists and differentiating antagonists between subtypes. The results of our study will act as a valuable tool for retrieving structurally diverse compds. with desired biol. activities

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese

10/513699


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (preparation and structure activity relations of tricyclic imidazoline derivatives as potent and selective adenosine A1 receptor antagonists)
RN: 433246-53-8 CAPLUS
CN: 5H-Imidazo[2,1-i]purin-5-one, 4-[(8R)-8-ethyl-4,5,7,8-tetrahydro-5-oxo-4-propyl-3H-imidazo[2,1-i]purin-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN: 433246-58-3 CAPLUS
CN: 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-8-methyl-4-propyl-, (8R)- (CA INDEX NAME)

Absolute stereochemistry.



RN: 433246-91-4 CAPLUS
CN: Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[(8R)-8-ethyl-4,5,7,8-tetrahydro-5-oxo-4-propyl-3H-imidazo[2,1-i]purin-2-yl]- (CA INDEX NAME)

<12/04/2007>


Erich Leese

<12/04/2007>

Erich Leese


10/513699

Absolute stereochemistry.



RN: 433246-97-0 CAPLUS
CN: 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-4,8-dipropyl-, (8R)- (CA INDEX NAME)


Absolute stereochemistry.



RN: 433247-03-1 CAPLUS
CN: 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-7-methyl-4-propyl-, (7S)- (CA INDEX NAME)


Absolute stereochemistry.

10/513699



RN: 433247-09-7 CAPLUS
CN: 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-8-phenyl-4-propyl-, (8R)- (CA INDEX NAME)


Absolute stereochemistry.



RN: 433247-14-4 CAPLUS
CN: 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-7-methyl-4-propyl-, (7R)- (CA INDEX NAME)


Absolute stereochemistry.

10/513699



RN: 433247-25-7 CAPLUS
CN: 5H-Imidazo[2,1-i]purin-5-one, 8-(1,1-dimethylethyl)-3,4,7,8-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-4-propyl-, (8R)- (CA INDEX NAME)

Absolute stereochemistry.



RN: 433247-31-5 CAPLUS
CN: 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-8-(2-methylpropyl)-4-propyl-, (8R)- (CA INDEX NAME)


Absolute stereochemistry.

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese




RN 433247-37-1 · CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-2-(4-hydroxycyclo[2.2.2]oct-1-yl)-8-(phenylmethyl)-4-propyl-, (8R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433247-50-6 · CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-2-(4-hydroxycyclo[2.2.2]oct-1-yl)-4-propyl- (CA INDEX NAME)



RN 433247-74-6 · CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-3,4,7,8-tetrahydro-2-(4-hydroxycyclo[2.2.2]oct-1-yl)-4-propyl-, (8S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433247-84-8 · CAPLUS
 CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[(8S)-8-ethyl-4,5,7,8-tetrahydro-5-oxo-4-propyl-3H-imidazo[2,1-i]purin-2-yl]- (CA INDEX NAME)


Absolute stereochemistry.

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese




RN 433248-07-8 · CAPLUS
 CN Pyrimido[2,1-i]purin-5(3H)-one, 4,7,8,9-tetrahydro-2-(4-hydroxycyclo[2.2.2]oct-1-yl)-9-methyl-4-propyl-, (9R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433248-11-4 · CAPLUS
 CN Pyrimido[2,1-i]purin-5(3H)-one, 9-ethyl-4,7,8,9-tetrahydro-2-(4-hydroxycyclo[2.2.2]oct-1-yl)-4-propyl-, (9R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 917762-86-8 · CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-2-(1-hydroxycyclo[2.2.2]oct-4-yl)-8-[(1S)-1-methylpropyl]-4-propyl-, (8R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 917762-90-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and structure activity relations of tricyclic imidazoline derivs. as potent and selective adenosine A1 receptor antagonists)
 RN 917762-90-4 · CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-3,4,7,8-tetrahydro-2-(1-hydroxycyclo[2.2.2]oct-4-yl)-4-propyl-, (8R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 433246-48-1
 CMP C20 H29 N5 O2


Absolute stereochemistry.

<12/04/2007>

Erich Leese

<12/04/2007>

Erich Leese



CM 2

CRN 76-05-1
CMF C2 H F3 O2

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:1298051 CAPLUS
 DOCUMENT NUMBER: 144:184409
 TITLE: Glucose concentration-dependent potentiation of insulin secretion by a new chemical entity, KCP256
 AUTHOR(S): Moro, Kiyoshi; Takasaki, Kotaro; Kato, Yoshihito; Yanai, Hiroshi; Ueno, Kimihisa; Ichimura, Michiaki; Kusaka, Hideaki; Nomoto, Yuji; Higo, Katsuya; Nakaniishi, Satoshi
 CORPORATE SOURCE: Drug Discovery Research Laboratories, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co., Ltd., 1188 Shimotogari, agazumi-cho, Shizuoka, Japan
 SOURCE: European Journal of Pharmacology (2005), 528(1-3), 176-182
 CODEN: EJPHAZ; ISSN: 0014-2999
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The insulinotropic activity of KCP256 [(R)-8-benzyl-2-cyclopentyl-7,8-dihydro-4-propyl-1H-imidazo[2,1-1]purin-5(4H)-one hydrochloride] was examined using MIN6 cells (a pancreatic B-cell line) and pancreatic islets isolated from rats. Unlike sulfonylurea anti-diabetic drugs, KCP256 dose-dependently (0.1-10 μ M) enhanced insulin secretion from

MIN6 cells and its insulinotropic effect was exerted only at high concns. of glucose (3.3-22 mM) but not at low concns. of glucose (3.3-5.5 mM). Furthermore, the action mechanism of KCP256 was different because, unlike sulfonylurea drugs, KCP256 did not displace the binding of [3 H]glibenclamide, and did not inhibit the β 2R β 2 efflux nor KATP channel activity. In isolated islets, KCP256 also enhanced insulin secretion in a dose- and glucose-concentration-dependent manner. Plasma levels of insulin after glucose challenge in KCP256-administered rats were higher than those in vehicle-administered animals, indicating that KCP256 can enhance insulin secretion in vivo. Since the insulinotropic activity of KCP256 only occurs at high concns. of glucose, this novel drug may exhibit a decreased risk of drug-induced hypoglycemia compared with sulfonylureas drugs when treating patients with diabetes.


IT 254426-47-6, KCP 256

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (glucose concentration-dependent potentiation of insulin secretion by a new chemical entity, KCP256)

RN 254426-47-6 CAPLUS

CN SH-Imidazo[2,1-1]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:1140156 CAPLUS
 DOCUMENT NUMBER: 143:416601
 TITLE: Human adenosine A3 receptor leads to intracellular Ca²⁺ mobilization but is insufficient to activate the signaling pathway via phosphoinositide 3-kinase γ in mice
 AUTHOR(S): Yamano, Kazuya; Inoue, Miho; Masaki, Shigehiro; Sakai, Mayumi; Ichimura, Michio; Sato, Mitsu
 CORPORATE SOURCE: Tokyo Research Laboratories, Kyowa Hakko Kogyo Co. Ltd., Machida-shi, Tokyo, 194-8533, Japan
 SOURCE: Biochemical Pharmacology (2005), 70(10), 1487-1496
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Selective antagonists for the adenosine A3 receptor (AA3R), a member of the G protein-coupled receptors, have been indicated as potential drugs

<12/04/2007>

Erich Leese

<12/04/2007>


Erich Leese

for anti-asthma or anti-inflammation. However, potent antagonists for the rodent AA3R have not been identified. To evaluate the pharmacol. effects of human AA3R antagonists in mice, the authors here generated AA3R-humanized mice, in which the mouse AA3R gene was replaced by its human counterpart. The expression levels of human AA3R in the AA3R-humanized mice were equivalent to those of mouse AA3R in wild-type mice. Elevation of the intracellular Ca²⁺ concentration induced by an AA3R agonist

was observed in bone marrow-derived mast cells from the AA3R-humanized mice and this Ca²⁺ mobilization was completely antagonized by a human AA3R antagonist. However, antigen-dependent degranulation was not potentiated by the AA3R agonist in the mast cells from AA3R-humanized mice. The agonist-stimulated human AA3R did not lead to the phosphorylation of either extracellular signal-regulated kinase 1/2 or protein kinase B in AA3R-humanized mice. The rate of human AA3R internalization in the mast cells was also markedly decreased compared with that of mouse AA3R in the mast cells. These results demonstrate that the human AA3R is insufficient to activate phosphoinositide 3-kinase γ -dependent signaling pathways in mice, probably due to the uncoupling of member(s) of the G proteins, which are capable of activating phosphoinositide 3-kinase γ , to the human AA3R, despite the mouse G protein(s) responsible for the Ca²⁺ elevation are coupled with the human AA3R.

IT 206129-88-6, KR 26777
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (purinergic antagonist; human adenosine A3 receptor mobilization of intracellular calcium independent of signaling by phosphoinositide kinase pathway in bone marrow mast cells from receptor transfected mice)

RN 206129-88-6 CAPLUS
 CN SH-Imidazo[2,1-1]purin-5-one, 2-(4-bromophenyl)-3,4,7,8-tetrahydro-4-propyl- (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:703873 CAPLUS
 DOCUMENT NUMBER: 143:338940
 TITLE: Autocorrelation of Molecular Electrostatic Potential Surface Properties Combined with Partial Least Squares Analysis as New Strategy for the Prediction of the Activity of Human A3 Adenosine Receptor Antagonists
 AUTHOR(S): Moro, Stefano; Bacilieri, Magdalena; Cacciari, Barbara; Spalluto, Giampiero
 CORPORATE SOURCE: Molecular Modeling Section, Dipartimento di Scienze Farmaceutiche, Universita di Padova, Padua, I-35131.

SOURCE: Italy
 Journal of Medicinal Chemistry (2005), 48(18), 5698-5704
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The combination of mol. electrostatic potential (MEP) surface properties (autocorrelation vectors) with the conventional partial least squares (PLS) anal. has been used for the prediction of the human A3 receptor antagonist activities. Three-hundred-fifty-eight structurally diverse human A3 receptor antagonists have been utilized to generate a novel ligand-based three-dimensional structure-activity relation. Remarkably, our chemical library includes all 21 important chemical classes of human A3 antagonists currently discovered, and it represents the largest mol. collection used to generate a general human A3 antagonist structure-activity relation. A robust quant. model has been obtained as described by both cross-validated correlation coefficient (rcv = 0.81) and prediction capability (rpred = 0.82). The proposed MEP/PLS approach can be considered as an alternative hit identification tool in virtual screening applications.

IT 44717-56-0 453591-60-1 543699-91-8


734528-03-1 788151-37-1

RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
 AB mol. electrostatic potential surface properties combined with partial least squares anal. for prediction of activity of human A3 adenosine receptor antagonists)

RN 44717-56-0 CAPLUS

CN SH-Imidazo[2,1-1]purin-5-one, 8-ethyl-3,4,7,8-tetrahydro-1,4-dimethyl-2-[(1E)-2-phenylethynyl]-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 453591-60-1 CAPLUS
 CN SH-Imidazo[2,1-1]purin-5-one, 8-ethyl-3,4,7,8-tetrahydro-1,4-dimethyl-2-[(1E)-2-phenylethynyl]-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese




RN 543699-91-8 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-4-methyl-2-phenyl- (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 734528-03-1 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-1-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 768151-37-1 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-4-methyl-2-[(1R)-2-phenylethényl]-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005158670 CAPLUS
DOCUMENT NUMBER: 142:261549
TITLE: Preparation of imidazo[1,2-c]pyrazolo[4,3-c]pyrimidine derivatives as glutamate racemase inhibitors
INVENTOR(S): Bassrab, Gregory S.; Byermann, Charles J.; Govararam, Madhusudhan R.; Green, Olyinka; Kiely, Andrew; Macpherson, Lawrence J.; Morningstar, Marshall L.; Thanh, Nguyen
PATENT ASSIGNEE(S): AstraZeneca AB, Sweden; AstraZeneca UK Limited
SOURCE: PCT Int. Appl. 76 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2004-0B3464	A1	20040224	MO 2004-0B3464	20040812	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BO, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LV, LK, LR, LS, LT, LV, MA, MD, ME, MN, MR, MU, NA, NI, NO, NZ, OM, PO, PL, PT, RO, RU, SC, SD, SE, SO, SU, OL, BY, TZ, TM, TT, TT, TZ, TZ, UD, UG, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BM, OM, GB, KB, LG, MW, MZ, NA, BD, BL, TZ, UD, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BW, BO, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CO, CI, CM, GA, GN, GO, GU, ML, MR, NE, SN, TD, TG	EP 2004-743692	A1	20040607	20040812	
R: AT, BE, CH, DR, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BO, CZ, BE, HU, PL, SK	JP 2007502307	T	20070208	JP 2006-523672	20040812
JP 2006252781	A1	20061109	US 2006-567797	20060209	
PRIORITY APPLN. INFO.: US 2003-495615P	US 2003-495615P	P	20030815	MO 2004-0B3464	20040812

OTHER SOURCE(S): CASREACT 142:261549, MARPAT 142:261549


GI

<12/04/2007>


Erich Leese

<12/04/2007>


Erich Leese




AB Title compds. represented by the formula I (wherein A = N or (un)substituted C; R = H, halo, (un)substituted alkyl, sulfide, etc.; R2 = H, (un)substituted (cyclo)alkyl, alkenyl, aryl, etc.; R3 = (un)substituted hetero(b) cyclic ring; and pharmaceutically acceptable salts thereof) were prepared as glutamate racemase inhibitors. For example, II was given in a multi-step synthesis starting from the reaction of 6-chlorouracil with cyclopropylmethyl bromide. I showed inhibition of glutamate racemase with IC50 values of less than 400 uM. Thus, I and their pharmaceutical compns. are useful as glutamate racemase inhibitors for the treatment or prophylaxis of H. pylori infection.
IT 845729-06-0P, 5-[8-((6-chloroquinolin-4-yl)methyl)-6-isobutyl-5-oxo-2,5,6,8-tetrahydro-3H-imidazol-2-yl]cyclopropo[4,3-e]pyrimidin-9-yl]-1-methyl-1H-pyrrole-3-carbonitrile (cyclopropylmethyl)-5-oxo-2,5,6,8-tetrahydro-3H-imidazol-2-yl]cyclopropo[4,3-e]pyrimidin-9-yl]-1-methyl-1H-pyrrole-3-carbonitrile 845729-08-0P, 5-[8-((6-chloroquinolin-4-yl)methyl)-6-(cyclopropylmethyl)-3-methyl-5-oxo-2,5,6,8-tetrahydro-3H-imidazol-2-yl]cyclopropo[4,3-e]pyrimidin-9-yl]-1-methyl-1H-pyrrole-3-carbonitrile 845729-09-1P, 845729-10-4P
845729-11-5P, 845729-12-6P, 5-[9-((6-Chloroquinolin-4-yl)methyl)-7-(cyclopropylmethyl)-6-oxo-2,3,4,6,7,9-hexahdropyrazolo[4,3-e]pyrimido[1,2-c]pyrimidin-10-yl]-1-methyl-1H-pyrrole-3-carbonitrile
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidine derivs. as glutamate racemase inhibitors)
RN 845729-06-8 CAPLUS
CN 1H-Pyrrole-3-carbonitrile, 5-[8-((6-chloro-4-quinolinyl)methyl)-2,5,6,8-tetrahydro-6-(2-methylpropyl)-5-oxo-3H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-9-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 845729-07-9 CAPLUS
CN 1H-Pyrrole-3-carbonitrile, 5-[8-((6-chloro-4-quinolinyl)methyl)-6-(cyclopropylmethyl)-2,5,6,8-tetrahydro-5-oxo-3H-imidazo[1,2-c]pyrimidin-9-yl]-1-methyl- (9CI) (CA INDEX NAME)



RN 845729-08-0 CAPLUS
CN 1H-Pyrrole-3-carbonitrile, 5-[8-((6-chloro-4-quinolinyl)methyl)-6-(cyclopropylmethyl)-2,5,6,8-tetrahydro-5-methyl-5-oxo-3H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-9-yl]-1-methyl- (9CI) (CA INDEX NAME)




<12/04/2007>

Erich Leese

<12/04/2007>


Erich Leese

RN 845729-09-1 CAPLUS
 CN 1H-Pyrrole-3-carbonitrile, 5-[(6-chloro-4-quinolinyl)methyl]-6-(cyclopropylmethyl)-2,5,6,8-tetrahydro-2-methyl-5-oxo-3H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-9-yl]-1-methyl- (9CI) (CA INDEX NAME)




RN 845729-10-4 CAPLUS
 CN 1H-Pyrrole-3-carbonitrile, 5-[(3R)-8-[(6-chloro-4-quinolinyl)methyl]-6-(cyclopropylmethyl)-2,5,6,8-tetrahydro-3-methyl-5-oxo-3H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-9-yl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 845729-11-5 CAPLUS
 CN 1H-Pyrrole-3-carbonitrile, 5-[(3S)-8-[(6-chloro-4-quinolinyl)methyl]-6-(cyclopropylmethyl)-2,5,6,8-tetrahydro-3-methyl-5-oxo-3H-imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-9-yl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 845729-12-6 CAPLUS
 CN 1H-Pyrrole-3-carbonitrile, 5-[(6-chloro-4-quinolinyl)methyl]-4-(cyclopropylmethyl)-2,4,5,7,8,9-hexahydro-5-oxopyrazolo[4,3-e]pyrimido[1,2-c]pyrimidin-1-yl]-1-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 46 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2004:965256 CAPLUS
 DOCUMENT NUMBER: 141:410951
 TITLE: Preparation of fused pyrimidine derivatives for treatment of diabetes
 INVENTOR(S): Nakajima, Takao; Ueno, Kimihisa; Nomoto, Yuji; Matsumoto, Yuichi; Yano, Hiroshi; Nakaniishi, Satoshi; Takasaki, Kotaro; Kusaka, Hideaki
 PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 40 pp.
 DOCUMENT TYPE: Patent
 CODEN: PIAKX02
 LANGUAGE: Japanese

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese

FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096111	A1	20041111	WO 2004-35889	20040423
W: AE, AG, AL, AR, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DO, DZ, EC, ES, EO, FI, GB, GD, GE, GH, GR, HR, HU, ID, IL, IN, IS, JP, KE, KO, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MO, MW, MX, MZ, NA, NI, NO, NZ, OM, PO, PT, RO, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GH, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BO, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
AU 2004234246	A1	20041111	AU 2004-234245	20040423
CA 2523763	A1	20041111	CA 2004-2523763	20040423
EP 1637532	A1	20060322	EP 2004-729197	20040423
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1777608	A	20060524	CN 2004-80010487	20040423
US 2006252780	A1	20061109	US 2005-554254	20051024
PRIORITY APPLN. INFO.:			JP 2003-121287	A 20030425
			WO 2004-35890	W 20040423

OTHER SOURCE(S): MARPAT 141:410951
 GI



AB The title fused pyrimidine derive, represented by the formula I [wherein R1 = H, (un)substituted alkyl, aralkyl, aryl, or heteroaryl; n = 0-3; X1 and X2 = independently H, (un)substituted alkyl, aralkyl, aryl, or heteroaryl; ring A = pyrrole, pyrazole, etc.] and pharmaceutically acceptable salts thereof are prepared for the treatment of diabetes. For example, the compound II was prepared in a multi-step synthesis. I showed significant promoting effect on insulin secretory activity at the concentration of 1.0 μ M.


IT 791071-38-0P 791071-39-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of fused pyrimidine derivs. for treatment of diabetes)

RN 791071-38-0 CAPLUS
 CN 5H-Imidazo[1,2-c]pyrazolo[3,2-e]pyrimidin-5-one, 8-cyclopentyl-2,3,6,8-


tetrahydro-2-(phenylmethyl)-6-propyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 791071-39-1 CAPLUS
 CN 5H-Imidazo[1,2-c]pyrazolo[3,2-e]pyrimidin-5-one, 2-cyclopentyl-2,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 791071-28-8P 791071-29-9P 791071-30-2P
 791071-31-3P 791071-32-4P 791071-33-5P
 791071-34-6P 791071-35-7P 791071-36-8P
 791071-37-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (drug candidate; preparation of fused pyrimidine derivs. for treatment of diabetes)

RN 791071-28-8 CAPLUS
 CN 5H-Imidazo[1,2-c]pyrazolo[3,2-e]pyrimidin-5-one, 2,3,6,7-tetrahydro-8-phenyl-2-(phenylmethyl)-6-propyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<12/04/2007>

Erich Leese

<12/04/2007>


Erich Leese

10/513699




RN 791071-29-9 CAPLUS
 CN 5H-Imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-one, 1,4,7,8-tetrahydro-2-phenyl-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 791071-30-2 CAPLUS
 CN 5H-Imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-one, 2,3,6,8-tetrahydro-2-phenyl-2-(phenylmethyl)-6-propyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 791071-31-3 CAPLUS
 CN 5H-Imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-one, 2-[(4-fluorophenyl)methyl]-2,3,6,8-tetrahydro-2-phenyl-6-propyl- (9CI) (CA INDEX NAME)


10/513699



RN 791071-32-4 CAPLUS
 CN 5H-Imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-one, 2-[(4-chlorophenyl)methyl]-2,3,6,8-tetrahydro-2-phenyl-6-propyl-, (9CI) (CA INDEX NAME)



RN 791071-33-5 CAPLUS
 CN 5H-Imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-one, 2,3,6,8-tetrahydro-2-phenyl-6-propyl-2-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 791071-34-6 CAPLUS
 CN 5H-Imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-one, 8-cyclopentyl-2,3,6,8-tetrahydro-2-(phenylmethyl)-6-propyl-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<12/04/2007>

Erich Leese

<12/04/2007>

Erich Leese


10/513699



● HCl


RN 791071-35-7 CAPLUS
 CN 5H-Imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-one, 8-cyclopentyl-2,3,6,8-tetrahydro-2-phenyl-6-propyl-2-(4-pyridinylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 791071-36-8 CAPLUS
 CN 5H-Imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-one, 2,4,7,8-tetrahydro-2-phenyl-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 791071-37-9 CAPLUS
 CN 5H-Imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-one, 2-cyclopentyl-2,4,7,8-

10/513699

tetrahydro-8-(phenylmethyl)-4-propyl-, monohydrochloride, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

IT 791071-41-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate, preparation of fused pyrimidine derivs. for treatment of diabetes)

RN 791071-41-5 CAPLUS
 CN 5H-Imidazo[1,2-c]pyrazolo[4,3-e]pyrimidin-5-one, 9-chloro-2,3,6,7-tetrahydro-8-phenyl-2-(phenylmethyl)-6-propyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 46 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2004:648390 CAPLUS
 DOCUMENT NUMBER: 141:185092
 TITLE: Combination of a phosphodiesterase IV (PDE IV) inhibitor and a tumor necrosis factor α (TNF- α) antagonist for the treatment of PDE IV-related conditions and TNF- α -related conditions
 INVENTOR(S): Warner, James M.

<12/04/2007>

Erich Leese

<12/04/2007>

Erich Leese

10/513699

PATENT ASSIGNEE(S): **Pharmacia Corporation, USA**SOURCE: **PCT Int. Appl. 66 pp.**DOCUMENT TYPE: **Patent**LANGUAGE: **English**FAMILY ACC. NUM. COUNT: **1**


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004067006	A1	20040812	WO 2004-IB616	20040123
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MO, MK, MN, MW, MX, MZ, NA, NI US 2006083714	A1	20060420	US 2004-500266	20040618
PRIORITY APPLN. INFO.:			US 2003-442881P	P 20030127
			WO 2004-IB616	W 20040123

AB The invention discloses therapeutic combinations and methods for the treatment of inflammatory conditions and diseases. In particular, the invention discloses treatments and methods for PDE IV-related conditions and for TNF- α -related conditions using a combination of a PDE IV inhibitor and a TNF- α antagonist.

IT 19589-73-9 CAPLUS
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (phosphodiesterase IV inhibitor-tumor necrosis factor α antagonist combination for treatment of PDE IV-related conditions and TNF- α -related conditions)

RN 19589-73-9 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-3,4-dipropyl- (9CI) (CA INDEX NAME)



14 ANSWER 10 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:262686 CAPLUS

DOCUMENT NUMBER: 141:16876

TITLE: Cyclic AMP phosphodiesterase 4 isoenzyme inhibitory activity of (R)- and (S)-isomer of 7-methyl- or 8-alkyl-4,5,7,8-tetrahydroimidazo[2,1-i]-purin-5-one

AUTHOR(S): Suzuki, Hiroyuki; Nomura, Masaki; Miyamoto, Ken-ichi; Sawanishi, Hiroyuki; Yamamoto, Kenji

CORPORATE SOURCE: Department of Synthetic Chemistry, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, 920-1181, Japan

SOURCE: Biological & Pharmaceutical Bulletin (2004), 27(3), 357-360
 CODEN: BPBLEO; ISSN: 0918-6158

<12/04/2007>

Erich Leese

10/513699


PUBLISHER: **Pharmaceutical Society of Japan**DOCUMENT TYPE: **Journal**LANGUAGE: **English**

AB We investigated the structure-activity relationship of the (R)- and (S)-isomer of 7-methyl- and 8-alkyl-tetrahydroimidazo[2,1-i]purines for phosphodiesterase 4 (PDE4) inhibitors. (S)-8-Isopropyl-3,4-dipropyl-imidazo[2,1-i]purine (S) exhibited both potent and selective PDE4 inhibitory activity.

IT 697793-23-0P 697793-24-1P 697793-25-2P
 697793-26-3P 697793-27-4P 697793-28-5P
 697793-29-6P 697793-30-9P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and structure-activity relationship studies of 8-alkyl-4,5,7,8-tetrahydroimidazo[2,1-i]-purin-5-one isomers as cAMP phosphodiesterase 4 isoenzyme inhibitors)


RN 697793-23-0 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-8-methyl-3,4-dipropyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 697793-24-1 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-8-methyl-3,4-dipropyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 697793-25-2 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-3,4,7,8-tetrahydro-3,4-dipropyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 697793-26-3 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-3,4,7,8-tetrahydro-3,4-dipropyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 697793-29-6 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-7-methyl-3,4-dipropyl-, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 697793-30-9 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-7-methyl-3,4-dipropyl-, (7S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 697793-31-0P 697793-32-1P 697793-33-2P
 697793-34-3P 697793-35-4P 697793-36-5P
 697793-37-6P 697793-38-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation and structure-activity relationship studies of 8-alkyl-4,5,7,8-tetrahydroimidazo[2,1-i]-purin-5-one isomers as cAMP phosphodiesterase 4 isoenzyme inhibitors)

RN 697793-31-0 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-methyl-1,4-dipropyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<12/04/2007> Erich Leese

10/513699




RN 697793-26-3 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-3,4,7,8-tetrahydro-3,4-dipropyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 697793-27-4 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-8-(1-methylethyl)-3,4-dipropyl-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 697793-28-5 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-8-(1-methylethyl)-3,4-dipropyl-, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/513699




RN 697793-29-6 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-7-methyl-3,4-dipropyl-, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 697793-30-9 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-7-methyl-3,4-dipropyl-, (7S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 697793-31-0P 697793-32-1P 697793-33-2P
 697793-34-3P 697793-35-4P 697793-36-5P
 697793-37-6P 697793-38-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation and structure-activity relationship studies of 8-alkyl-4,5,7,8-tetrahydroimidazo[2,1-i]-purin-5-one isomers as cAMP phosphodiesterase 4 isoenzyme inhibitors)

RN 697793-31-0 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-methyl-1,4-dipropyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<12/04/2007> Erich Leese

10/513699




RN 697793-32-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-methyl-1,4-dipropyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 697793-33-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-1,4-dipropyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 697793-34-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-1,4-dipropyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

<12/04/2007>


Erich Leese

10/513699




RN 697793-35-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(1-methylethyl)-1,4-dipropyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 697793-36-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(1-methylethyl)-1,4-dipropyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 697793-37-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-7-methyl-1,4-dipropyl-, (7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

<12/04/2007>

<12/04/2007>


Erich Leese

10/513699



RN 697793-38-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-7-methyl-1,4-dipropyl-, (7S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 697793-39-8P 697793-40-1P 697793-41-2P
 697793-42-3P 697793-43-4P 697793-44-5P
 697793-45-6P 697793-46-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and structure-activity relationship studies of 8-alkyl-1,4,5,7,8-tetrahydroimidazo[2,1-i]-purin-5-one isomers as cAMP phosphodiesterase 4 isoenzyme inhibitors)

RN 697793-39-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-methyl-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 697793-40-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-methyl-4-propyl-, (8S)-

10/513699


(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 697793-41-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 697793-42-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 697793-43-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(1-methylethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese




RN 697793-44-5 CAPLUS
CN 5H-Imidazo[2,1-1]purin-5-one, 1,4,7,8-tetrahydro-8-(1-methylethyl)-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 697793-45-6 CAPLUS
CN 5H-Imidazo[2,1-1]purin-5-one, 1,4,7,8-tetrahydro-7-methyl-4-propyl-, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 697793-46-7 CAPLUS
CN 5H-Imidazo[2,1-1]purin-5-one, 1,4,7,8-tetrahydro-7-methyl-4-propyl-, (7S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RR FORMAT

L4 ANSWER 11 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004101168 CAPLUS
DOCUMENT NUMBER: 140:151990
TITLE: Cell differentiation inductor
INVENTOR(S): Hasagawa, Kazuhide; Matsubara, Masahiro
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 62 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004011469	A1	20040205	WO 2003-JP9460	20030725
W: AE, AG, AL, AM, AT, AU, BE, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MO, MK, MN, MM, MX, MZ, NI, NO, NZ, OM, PO, PH, PL, PT, SD, SE, SI, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		RU: GH, OM, KE, LS, MM, MZ, SD, SL, TM, ZM, AM, AZ, BY, KG, KZ, MD, RU, TZ, AT, BE, BG, CY, CZ, DE, DK, ES, ES, FI, FR, GB, HU, IE, IL, LU, MC, NL, PT, RO, SE, SI, SK, TR, DE, DJ, CP, CO, CI, CM, GA, GN, GO, GW, HL, MR, NE, SN, TD, TO		
AU 2003252697	A1	20040216	AU 2003-252697	20030725
PRIORITY APPLN. INFO.:			JP 2002-218882	A 20020726
OTHER SOURCE(S):	MARPAT 140:151990		WO 2003-JP9460	W 20030725

GI



<12/04/2007>

Erich Leese

<12/04/2007>

Erich Leese

AB A cell differentiation inductor which contains as an active ingredient one member selected among a fused purine derivative represented by the formula I, a fused purine derivative represented by the formula II, and pharmacologically acceptable salts of these.

IT 180145-17-9 254426-38-5 254426-39-6

254426-40-9 254426-41-0 254426-44-3

254426-47-6 254426-48-2 254426-49-8

254426-50-1 254426-51-2 254426-52-3

254426-53-4 254426-54-5 254426-55-6

254426-56-7 254426-57-8 254426-58-9

254426-59-0 254426-61-4 254426-62-5

254426-76-1 254426-77-2 254426-78-3

254426-79-4 254426-80-7 254426-81-8

254426-83-0 254426-84-1 254426-89-6

254426-90-0 254426-91-0 254426-92-1

254426-93-2 254426-94-3 254426-95-4

254426-96-5 254427-01-5 254427-05-9

254427-06-0 254427-17-3 254427-18-4

254427-19-5 254427-20-8 254427-21-9

254427-22-5 254427-23-1 254427-24-2

348149-82-2 348165-49-1 348165-85-5

348165-93-3 348166-05-2 348166-06-3

348166-07-4 348166-21-2 348166-22-3

348166-24-5 348166-29-4 348166-30-3

348166-31-1 348167-01-6 348167-07-7

348167-08-2 348167-33-9 348167-44-2

348167-45-3 348167-46-4 348167-48-6

348167-49-7 348167-50-0 348167-51-1

348167-52-2 348167-56-6 348167-57-7

348167-59-9 348167-60-2 348167-61-3

348167-62-4 348167-63-5 348168-23-0

348169-43-7 348169-44-8 348169-46-0, SN 343

348169-52-3 348169-53-9 348169-56-2

348169-58-0 348169-72-2 348169-73-3

348169-79-9 348169-82-4 348169-83-5

348169-85-7 348362-73-2 349554-63-8

349554-73-0 349585-61-1 627876-24-8

627876-25-5 652146-46-8 652146-47-9

652146-48-5 652146-49-1 652146-50-4

652146-51-1 652146-52-6 652146-53-7

652146-54-5 652146-55-9 652146-56-0

652146-58-0 652146-60-1 652146-61-7

652146-63-9 652146-65-1 652146-67-3

652146-68-4 652146-70-0 652146-72-0

652146-74-2 652146-76-4 652146-78-6

652146-84-4 652146-88-8 652146-89-9

652146-91-3 652146-93-5 652147-03-0

652147-05-2 652147-07-4 652147-09-6

652147-12-1 652147-14-3 652147-16-5

652147-20-1 652147-22-3 652147-24-5

652147-26-7 652147-28-9 652147-30-3

652147-32-5 652147-34-7 652147-36-9

652147-38-1 652147-51-8 652147-58-5

652147-60-9 652147-62-1 652147-63-2

652147-65-5 652147-71-2 652147-73-4

652147-75-6 652147-77-8 652147-79-0

652147-81-4 652147-82-5 652147-84-7

652147-86-9 652147-88-1 652147-93-8

652148-09-9 652148-12-4 652148-15-7

652148-25-9 652148-27-1 652148-28-2

652148-29-3 652148-30-6 652148-31-7

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PIV (Physical process); THU (Therapeutic use); BIOL (Biological studies); PROC (Process); USES (Uses) (fused purine derivative as cell differentiation inductors)

RN 180145-17-9 CAPLUS

CN 5H-Imidazo[2,1-1]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-4-propyl-2-tricyclo[3.1.1.0]1,7dec-1-yl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 254426-38-5 CAPLUS
CN 5H-Imidazo[2,1-1]purin-5-one, 2-cyclopentyl-8-ethyl-1,4,7,8-tetrahydro-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 254426-39-6 CAPLUS
CN 5H-Imidazo[2,1-1]purin-5-one, 2-cyclopentyl-8-ethyl-1,4,7,8-tetrahydro-4-propyl-, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/513699




RN 254426-40-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(1-methylethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 254426-41-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(1-methylethyl)-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 254426-44-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-butyl-2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-, (9CI) (CA INDEX NAME)

10/513699




RN 254426-47-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254426-48-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254426-49-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-((4-fluorophenyl)methyl)-1,4,7,8-tetrahydro-4-propyl-, (9CI) (CA INDEX NAME)


<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese


10/513699




RN 254426-50-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-((3-fluorophenyl)methyl)-1,4,7,8-tetrahydro-4-propyl-, (9CI) (CA INDEX NAME)



RN 254426-51-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-((4-chlorophenyl)methyl)-2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-, (9CI) (CA INDEX NAME)




RN 254426-52-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-((3-chlorophenyl)methyl)-2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-, (9CI) (CA INDEX NAME)




RN 254426-53-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-((2,6-dichlorophenyl)methyl)-1,4,7,8-tetrahydro-4-propyl-, (9CI) (CA INDEX NAME)


10/513699




RN 254426-54-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-((4-bromophenyl)methyl)-2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-, (9CI) (CA INDEX NAME)



RN 254426-55-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-((3-bromophenyl)methyl)-2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-, (9CI) (CA INDEX NAME)



RN 254426-56-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-((4-methoxyphenyl)methyl)-4-propyl-, (9CI) (CA INDEX NAME)



RN 254426-57-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-((4-nitrophenyl)methyl)-4-propyl-, (9CI) (CA INDEX NAME)


<12/04/2007>

Erich Leese

<12/04/2007>


Erich Leese

10/513699




RN 254426-58-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(4-(phenylmethoxy)phenyl)methyl]-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 254426-59-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(4-(phenylmethoxy)phenyl)methyl]-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 254426-61-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-(diphenylmethyl)-1,4,7,8-tetrahydro-4-propyl-, (9CI) (CA INDEX NAME)


10/513699




RN 254426-62-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(2-phenylethyl)-4-propyl-, (9CI) (CA INDEX NAME)



RN 254426-76-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(4-bromophenyl)methyl]-2-cyclohexyl-1,4,7,8-tetrahydro-4-propyl-, (9CI) (CA INDEX NAME)



RN 254426-77-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(4-chlorophenyl)methyl]-1,4,7,8-tetrahydro-2,4-dipropyl-, (9CI) (CA INDEX NAME)



RN 254426-78-3 CAPLUS

<12/04/2007>


Erich Leese

<12/04/2007>


Erich Leese

10/513699


CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(4-chlorophenyl)methyl]-2-cyclohexyl-1,4,7,8-tetrahydro-4-propyl-, (9CI) (CA INDEX NAME)



RN 254426-79-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(4-chlorophenyl)methyl]-2-cyclobutyl-1,4,7,8-tetrahydro-4-propyl-, (9CI) (CA INDEX NAME)




RN 254426-80-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(4-fluorophenyl)methyl]-1,4,7,8-tetrahydro-2,4-dipropyl-, (9CI) (CA INDEX NAME)




RN 254426-81-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclohexyl-8-[(4-fluorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl-, (9CI) (CA INDEX NAME)


10/513699




RN 254426-83-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-butyl-8-[(4-fluorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl-, (9CI) (CA INDEX NAME)



RN 254426-84-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(4-fluorophenyl)methyl]-2-(2-furanyl)-1,4,7,8-tetrahydro-4-propyl-, (9CI) (CA INDEX NAME)



RN 254426-85-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(3-fluorophenyl)methyl]-1,4,7,8-tetrahydro-2-(2-methylpropyl)-4-propyl-, (9CI) (CA INDEX NAME)



<12/04/2007>


Erich Leese

<12/04/2007>


Erich Leese

10/513699


RN 254426-90-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-8-[(3-fluorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)



RN 254426-91-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(2-fluorophenyl)methyl]-1,4,7,8-tetrahydro-2-(2-methylpropyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 254426-92-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(3-methylphenyl)methyl]-4-propyl- (9CI) (CA INDEX NAME)




RN 254426-93-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(3-iodophenyl)methyl]-4-propyl- (9CI) (CA INDEX NAME)


<12/04/2007>

Erich Leese


10/513699




RN 254426-94-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(2,3-difluorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)



RN 254426-95-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(2,5-difluorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)



RN 254426-96-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(2,5-dichlorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




RN 254427-01-5 CAPLUS
 CN Benzonitrile, 3-(1-(2-cyclopentyl-4,5,7,8-tetrahydro-5-oxo-4-propyl-1H-imidazo[2,1-i]purin-8-yl)methyl)- (9CI) (CA INDEX NAME)

<12/04/2007> Erich Leese


10/513699

10/513699


1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




RN 254427-19-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-[(3-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 254427-20-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(3-(2-fluorophenyl)phenyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




RN 254427-21-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(3-phenoxyphenyl)methyl]-4-propyl- (9CI) (CA INDEX NAME)



RN 254427-06-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(1-methyl-1-phenylethyl)-4-propyl- (9CI) (CA INDEX NAME)

RN 254427-17-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(4-(1,1-dimethylethyl)phenyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)



RN 254427-18-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(1,1'-biphenyl)-2-ylmethyl]-2-cyclopentyl-

<12/04/2007>


Erich Leese

<12/04/2007>


Erich Leese

10/513699


RN 254427-22-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-
 [(3-(trifluoromethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 254427-23-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(3,5-bis(trifluoromethyl)phenyl)methyl]-2-
 cyclopentyl-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




RN 254427-24-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-methyl-8-
 (phenylmethyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 348149-82-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-
 (4-pyridinylmethyl)-, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/513699




RN 348165-49-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-
 (4-pyridinylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348165-85-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-
 (2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 348165-93-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-
 (3-pyridinylmethyl)- (9CI) (CA INDEX NAME)


<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese


10/513699




RN 348166-05-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-
 (pyrazinylmethyl)- (9CI) (CA INDEX NAME)



RN 348166-06-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-
 (4-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)



RN 348166-07-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2,4-dipropyl-8-
 (4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 348166-21-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclohexyl-1,4,7,8-tetrahydro-4-propyl-8-
 (4-pyridinylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

<12/04/2007>


Erich Leese

10/513699


Absolute stereochemistry.



RN 348166-22-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(1,1-dimethylethyl)-1,4,7,8-tetrahydro-4-
 propyl-8-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 348166-24-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-4-propyl-8-(4-
 pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 348166-29-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-
 [(4-methysulfonyl)oxy]methyl-1-(phenylmethyl)-4-propyl- (9CI) (CA INDEX
 NAME)


<12/04/2007>

Erich Leese


10/513699




RN 348166-30-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-1-(methoxymethyl)-8-[(methylsulfonyloxy)methyl]-4-propyl- (9CI) (CA INDEX NAME)



RN 348166-31-4 CAPLUS
 CN 1H-Indole-1,3(2H)-dione, 2-[(2-cyclopentyl-4,5,7,8-tetrahydro-1-(methoxymethyl)-5-oxo-4-propyl-1H-imidazo[2,1-i]purin-8-yl)methyl]- (9CI) (CA INDEX NAME)



RN 348166-91-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-(1H-pyrazol-1-ylmethyl)- (9CI) (CA INDEX NAME)



<12/04/2007>


Erich Leese

<12/04/2007>


Erich Leese

10/513699


RN 348167-31-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(1H-imidazol-1-ylmethyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 348167-32-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-(1H-2,4-triazol-1-ylmethyl)- (9CI) (CA INDEX NAME)




RN 348167-33-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-(1H-pyrrrol-1-ylmethyl)- (9CI) (CA INDEX NAME)



RN 348167-44-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-bromo-1,4,7,8-tetrahydro-1,8-bis(phenylmethyl)-4-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/513699




RN 348167-45-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-1-(methoxymethyl)-2-(methylthio)-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348167-46-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-1,8-bis(phenylmethyl)-4-propyl-2-(1-pyrrolidinyl)-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348167-48-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-(4-morpholinyl)-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/513699




RN 348167-49-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-(1-hydroxycyclopentyl)-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348167-50-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purine-2-carboxaldehyde, 4,5,7,8-tetrahydro-5-oxo-1,8-bis(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348167-51-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(chloromethyl)-1,4,7,8-tetrahydro-1,8-bis(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<12/04/2007>

Erich Leese

<12/04/2007>


Erich Leese

10/513699




RN 348167-52-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-[(dimethylamino)methyl]-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348167-56-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-2-(1-piperidinylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348167-57-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(ethoxymethyl)-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/513699




RN 348167-59-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-[(4R,5R)-4,5-dimethyl-1,3-dioxolan-2-yl]-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348167-60-2 CAPLUS
 CN 1H-Imidazo[2,1-i]purine-2-carboxylic acid, 4,5,7,8-tetrahydro-5-oxo-1,8-bis(phenylmethyl)-4-propyl, methyl ester, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348167-61-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-(1-hydroxy-1-methylethyl)-1,8-bis(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

<12/04/2007>


Erich Leese

<12/04/2007>

Erich Leese


10/513699

Absolute stereochemistry.




RN 348167-62-4 CAPLUS
 CN Piperidine, 4-[(8R)-4,5,7,8-tetrahydro-5-oxo-8-(phenylmethyl)-4-propyl-1H-imidazo[2,1-i]purin-2-yl]carbonyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348167-63-5 CAPLUS
 CN Morpholine, 4-[(8R)-4,5,7,8-tetrahydro-5-oxo-8-(phenylmethyl)-4-propyl-1H-imidazo[2,1-i]purin-2-yl]carbonyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348168-23-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(1-ethoxyethyl)-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)


10/513699

Absolute stereochemistry.




RN 348169-43-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-[(4R,5R)-4,5-dimethyl-1,3-dioxolan-2-yl]-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348169-44-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-[(phenylmethoxy)methyl]-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348169-46-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-(methoxyphenylmethyl)-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

<12/04/2007>


Erich Leese

<12/04/2007>

Erich Leese


10/513699

Absolute stereochemistry.




RN 348169-52-0 CAPLUS
CN 1H-Imidazo[2,1-i]purine-2-propanoic acid, 4,5,7,8-tetrahydro-5-oxo-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348169-53-9 CAPLUS
CN Piperidine, 4-[(8S)-8-(1,1-dimethylethyl)-4,5,7,8-tetrahydro-5-oxo-4-propyl-1H-imidazo[2,1-i]purin-2-yl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




<12/04/2007>

Erich Leese

10/513699


RN 348169-56-2 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-[(ethylthio)methyl]-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348169-58-4 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-[(ethylsulfonyl)methyl]-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348169-72-2 CAPLUS
CN 5H-Imidazo[2,1-i]purin-4(5H)-acetamide, 2-cyclopentyl-7,8-dihydro-5-oxo-8-(phenylmethyl)-N-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348169-73-3 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-[3-(2-oxo-3-oxazolidinyl)propyl]-8-(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

<12/04/2007>


Erich Leese

10/513699

RN 348169-83-5 CAPLUS
CN Pyrimido[2,1-i]purin-5(1H)-one, 2-(ethoxymethyl)-4,7,8,9-tetrahydro-8-(phenylmethyl)-4-propyl- (9CI) (CA INDEX NAME)




RN 348169-85-7 CAPLUS
CN Pyrimido[2,1-i]purin-5(1H)-one, 2-cyclopentyl-4,7,8,9-tetrahydro-4-propyl-8-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 348362-73-2 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclobutyl-1,4,7,8-tetrahydro-4-propyl-8-(4-pyridinylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 349554-63-8 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-2-(tetrahydro-2-furanyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/513699

Absolute stereochemistry.




RN 348169-79-9 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-[2-(2-methyl-1,3-dioxolan-2-yl)ethyl]-8-(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348169-82-4 CAPLUS
CN Pyrimido[2,1-i]purin-5(1H)-one, 2-(ethoxymethyl)-4,7,8,9-tetrahydro-9-(phenylmethyl)-4-propyl-, (9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




<12/04/2007>

Erich Leese

10/513699


RN 348169-56-2 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-[(ethylthio)methyl]-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348169-58-4 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-[(ethylsulfonyl)methyl]-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348169-72-2 CAPLUS
CN 5H-Imidazo[2,1-i]purin-4(5H)-acetamide, 2-cyclopentyl-7,8-dihydro-5-oxo-8-(phenylmethyl)-N-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348169-73-3 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-[3-(2-oxo-3-oxazolidinyl)propyl]-8-(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

<12/04/2007>


Erich Leese

10/513699




RN 349564-73-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-(3-hydroxypropyl)-8-(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 349585-61-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-[trans-4-(aminomethyl)cyclohexyl]-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627876-24-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-2-(tetrahydro-2H-pyran-4-yl)-, (8R)- (9CI) (CA INDEX NAME)

<12/04/2007>

Erich Leese


10/513699

Absolute stereochemistry.




RN 627876-25-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-(trans-4-hydroxycyclohexyl)-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652146-46-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-4-propyl-2-tricyclo[3.3.1.13.7]dec-1-yl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




<12/04/2007>

Erich Leese

10/513699


RN 652146-47-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(1-methylethyl)-4-propyl-2-tricyclo[3.3.1.13.7]dec-1-yl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 652146-48-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(1-methylethyl)-4-propyl-2-tricyclo[3.3.1.13.7]dec-1-yl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 652146-49-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-4-propyl-2-tricyclo[3.3.1.13.7]dec-1-yl- (9CI) (CA INDEX NAME)



RN 652146-50-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-methyl-4-propyl-, (8S)- (9CI) (CA INDEX NAME)


10/513699

Absolute stereochemistry.




RN 652146-51-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(2-methylpropyl)-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652146-52-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-(1,1-dimethylethyl)-1,4,7,8-tetrahydro-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652146-53-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-(cyclohexylmethyl)-2-cyclopentyl-1,4,7,8-

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese

10/513699

tetrahydro-4-propyl-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 652146-54-8 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-phenyl-4-propyl-, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 652146-55-9 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-1-methyl-8-(phenylmethyl)-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652146-56-0 CAPLUS


<12/04/2007>

Erich Leese

10/513699

CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 652146-58-2 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 652146-60-6 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-1,8-bis(phenylmethyl)-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652146-61-7 CAPLUS


CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-2,4-dipropyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

<12/04/2007>

Erich Leese


10/513699



RN 652146-63-9 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopropyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 652146-65-1 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclobutyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652146-67-3 CAPLUS


CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclohexyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

<12/04/2007>

Erich Leese


10/513699



RN 652146-68-4 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-2-tricyclo[3.3.1.1,7]dec-1-yl-, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 652146-70-8 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 2-(cyclopentylmethyl)-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652146-72-0 CAPLUS


CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-(1-methylethyl)-8-(phenylmethyl)-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

<12/04/2007>


Erich Leese

10/513699




RN 652146-74-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(3-furanyl)-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652146-76-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(1,1-dimethylethyl)-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 652146-78-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-2-(3-thienyl)-, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/513699




RN 652146-84-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclobutyl-8-[(4-fluorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652146-88-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(4-fluorophenyl)methyl]-2-(3-furanyl)-1,4,7,8-tetrahydro-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652146-89-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(1,1-dimethylethyl)-8-[(4-fluorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

<12/04/2007>


Erich Leese

<12/04/2007>


Erich Leese

10/513699


Absolute stereochemistry.



RN 652146-91-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-butyl-8-[(3-fluorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl-, (8S)- (9CI) (CA INDEX NAME)




RN 652146-93-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclobutyl-8-[(3-fluorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl-, (8S)- (9CI) (CA INDEX NAME)



RN 652147-03-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-(1,1-dimethylethyl)-1,4,7,8-tetrahydro-4-propyl-2-tricyclo[3.3.1.13,7]dec-1-yl-, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/513699




RN 652147-05-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-(1,1-dimethylethyl)-2-(3-furanyl)-1,4,7,8-tetrahydro-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652147-07-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-(1,1-dimethylethyl)-2-(3,5-dimethyl-4-isoxazolyl)-1,4,7,8-tetrahydro-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652147-09-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2,8-bis(1-methylethyl)-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

<12/04/2007>


Erich Leese

<12/04/2007>

Erich Leese


10/513699

Absolute stereochemistry.




RN 652147-12-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-4-ethyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652147-14-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-4-(cyclopropylmethyl)-1,4,7,8-tetrahydro-8-(phenylmethyl)-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 652147-16-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(cyclopentylmethyl)-4-ethyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-, (8S)- (9CI) (CA INDEX NAME)

<12/04/2007>

Erich Leese


10/513699

Absolute stereochemistry.




RN 652147-20-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(4-hydroxyphenyl)methyl]-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652147-22-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(3-pyridinyl)-4-ethyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 652147-24-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(3-pyridinyl)-4-propyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-, (8S)- (9CI) (CA INDEX NAME)

<12/04/2007>

Erich Leese


10/513699

Absolute stereochemistry.




RN 652147-26-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(2,2,3,3-tetramethylcyclopropyl)-4-propyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652147-28-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(1,3-benzodioxol-5-yl)-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 652147-30-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(1,3-benzodioxol-5-yl)-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

<12/04/2007>

Erich Leese


10/513699

Absolute stereochemistry.




RN 652147-32-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-pyrazinyl-4-propyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652147-34-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(2-thienyl)-4-propyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




<12/04/2007>

Erich Leese

10/513699


RN 652147-36-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-methyl-8-(phenylmethyl)-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 652147-38-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-phenyl-8-(phenylmethyl)-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652147-51-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(2-methyl-4-thiazolyl)methyl]-4-propyl- (9CI) (CA INDEX NAME)




RN 652147-58-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-[(1-methylcyclohexyl)-4-propyl-8-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)


<12/04/2007>

Erich Leese


10/513699




RN 652147-60-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 652147-62-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 4-(cyclopropylmethyl)-2-(1,1-dimethylethyl)-1,4,7,8-tetrahydro-8-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 652147-63-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-4-ethyl-1,4,7,8-tetrahydro-8-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




<12/04/2007>


Erich Leese

10/513699


RN 652147-65-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-(aminomethyl)-2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




RN 652147-71-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-(1H-benzimidazol-1-ylmethyl)-2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)



RN 652147-73-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-(chloromethyl)-2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




RN 652147-75-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(1-phenylaminomethyl)-4-propyl- (9CI) (CA INDEX NAME)




10/513699


RN 652147-77-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(1-piperidinylmethyl)-4-propyl- (9CI) (CA INDEX NAME)




RN 652147-79-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 652147-81-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(4-morpholinylmethyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 652147-82-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(4-phenylmethyl)-1-piperazinyl]methyl)-4-propyl- (9CI) (CA INDEX NAME)



<12/04/2007>


Erich Leese

<12/04/2007>


Erich Leese

10/513699


RN 652147-84-7 CAPLUS
 CN 5H-Imidazo[2,1-1]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(4-phenyl-1-piperazinyl)methyl]-4-propyl- (9CI) (CA INDEX NAME)



RN 652147-86-9 CAPLUS
 CN 5H-Imidazo[2,1-1]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(4-phenylmethyl)-1-piperidinyl]methyl]-4-propyl- (9CI) (CA INDEX NAME)




RN 652147-88-1 CAPLUS
 CN 5H-Imidazo[2,1-1]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(4-phenylmethyl)amino]methyl]-4-propyl- (9CI) (CA INDEX NAME)



RN 652147-93-8 CAPLUS
 CN 5H-Imidazo[2,1-1]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-2-(1-pyrrolidinyl)-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/513699




RN 652148-09-9 CAPLUS
 CN 5H-Imidazo[2,1-1]purin-5-one, 1,4,7,8-tetrahydro-2-(2-methoxyethyl)-8-(phenylmethyl)-4-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652148-12-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[(8R)-4,5,7,8-tetrahydro-5-oxo-8-(phenylmethyl)-4-propyl-1H-imidazo[2,1-1]purin-2-yl]-, 1,1-dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652148-15-7 CAPLUS
 CN Acetamide, N-[(trans-4-[(8R)-4,5,7,8-tetrahydro-5-oxo-8-(phenylmethyl)-4-propyl-1H-imidazo[2,1-1]purin-2-yl]cyclohexyl)methyl]- (9CI) (CA INDEX)

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese

10/513699


NAME)

Absolute stereochemistry.




RN 652148-25-9 CAPLUS
 CN 5H-Imidazo[2,1-1]purine-4-(5H)-acetic acid, 2-cyclopentyl-7,8-dihydro-5-oxo-8-(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652148-27-1 CAPLUS
 CN 5H-Imidazo[2,1-1]purin-5-one, 2-cyclopentyl-8-[(4-fluorophenyl)methyl]-1,4,7,8-tetrahydro-4-(2-hydroxyethyl)-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/513699


RN 652148-28-2 CAPLUS
 CN 5H-Imidazo[2,1-1]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-(2-hydroxy-2-methylpropyl)-8-(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 652148-29-3 CAPLUS
 CN 5H-Imidazo[2,1-1]purin-5-one, 2-(1,1-dimethylethyl)-1,4,7,8-tetrahydro-4-(3-hydroxypropyl)-8-(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652148-30-6 CAPLUS
 CN 5H-Imidazo[2,1-1]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-(3-hydroxy-3-methylbutyl)-8-(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 652148-31-7 CAPLUS

<12/04/2007>


Erich Leese

<12/04/2007>

Erich Leese

CN 5H-Imidazo[2,1-i]purin-5-one, 2-(1,1-dimethylethyl)-1,4,7,8-tetrahydro-4-(3-hydroxy-3-methylbutyl)-8-(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:65351 CAPLUS

DOCUMENT NUMBER: 140:264351

TITLE: Antinociceptive effects of novel A2B adenosine receptor antagonists

AUTHOR(S): Abo-Salem, Osama M.; Hayallah, Alaa M.; Bilkai-Gorzo, Andras; Filipek, Barbara; Zimmer, Andreas; Mueller, Christa E.

CORPORATE SOURCE: Laboratory of Molecular Neurobiology, Department of Psychiatry, University of Bonn, Bonn, Germany

SOURCE: Journal of Pharmacology and Experimental Therapeutics (2004), 308(1), 358-366

CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Caffeine, an adenosine A₁, A_{2A}, and A_{2B} receptor antagonist, is frequently used as an adjuvant analgesic in combination with nonsteroidal anti-inflammatory drugs or opioids. In this study, we have examined the effects of several specific adenosine receptor antagonists in an acute animal model of nociception. Several A2B-selective compd. showed antinociceptive effects in the hot-plate test. In contrast, A₁- and A_{2A}-selective compd. did not alter pain thresholds, and an A₁ adenosine receptor antagonist produced thermal hyperalgesia. Evaluation of psychostimulant effects of these compd. in the open field showed only small effects of some antagonists at high doses. Coadministration of low, subeffective doses of A2B-selective antagonists with a low dose of morphine enhanced the efficacy of morphine. Our results indicate that analgesic effects of caffeine are mediated, at least in part, by A2B adenosine receptors.

IT 439902-54-2, PDB 10

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(PDB 10; antinociceptive effects of novel A2B adenosine receptor antagonists)


RN 439902-54-2 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-4-methyl-2-(2,3,5-trichlorophenyl)-, (8R)- (9CI) (CA INDEX NAME)

<12/04/2007>

Erich Leese

Absolute stereochemistry.



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:991776 CAPLUS

DOCUMENT NUMBER: 140:35889

TITLE: Methods of searching for substance having antidiabetic effect

AUTHOR(S): Nakanishi, Satoshi; Yano, Hiroshi; Mori, Kiyotoshi; Matsuda, Yuzuru

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan

SOURCE: PCT Int. Appl., 20 pp.

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104804	A1	20031218	WO 2003-JP7351	20030610
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KO, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MO, MK, MN, MM, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, BG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, ER, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TO				
AU 2003244107	A1	20031222	AU 2003-244107	20030610
PRIORITY APPLN. INFO.:			JP 2003-1181	A 20030610
			JP 2002-158922	A 20020610
			WO 2003-JP7351	W 20030610

AB It is intended to provide a method of searching for a substance having an antidiabetic effect which comprises [1] the step of bringing a substance inhibiting the activity of the potassium-ATP channel of pancreatic β cells into contact with pancreatic β cells in the presence of a test

<12/04/2007>

Erich Leese

substance and measuring the cell response of the cells upon the contact, [2] the step of bringing the above substance inhibiting the activity of the potassium-ATP channel of pancreatic β cells into contact with the above cells in the absence of a test substance and measuring the cell response of the cells upon the contact, and [3] the step of comparing the obtained data and thus selecting a substance which inhibits the cell response of the above cells and a method of searching for a substance having an antidiabetic effect which comprises [1] the step of bringing a test substance into contact with pancreatic β cells having been desensitized to a compound having a sulfonylurea structure at a high glucose concentration and measuring the cell response of the cells upon the contact,

[2] the step of measuring the cell response of the above cells at a high glucose concentration, and [3] the step of comparing the obtained data and thus selecting a substance altering the cell response of the above cells from among the test substances.

IT 254426-47-6


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method for searching for substance having antidiabetic effect)

RN 254426-47-6 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:931526 CAPLUS

DOCUMENT NUMBER: 140:14538

TITLE: Method for searching condensed purine derivative having antidiabetic activity

AUTHOR(S): Ishiguro, Hiroki; Oshima, Yuko; Sugimoto, Seiji;

Matsubara, Masahiro; Ueno, Kimihisa; Mori, Kiyotoshi;

Nakanishi, Satoshi; Yano, Hiroshi

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan

SOURCE: PCT Int. Appl., 130 pp.

CODEN: PIIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003107962	A1	20031127	WO 2003-JP6137	20030516
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KO, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MO, MK, MN, MM, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, BG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, ER, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TO				
AU 2003231538	A1	20031202	AU 2003-231538	20030516
EP 2003151942	A1	20050316	EP 2003-725810	20030516
R: AT, BE, CH, DE, DK, ES, FR, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, PL, RO, RU, SK, CY, CZ, DE, DK, ER, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TO				
CN 1668759	A	20050514	CN 2003-816846	20030516
PRIORITY APPLN. INFO.:			JP 2002-143599	A 20020517
			WO 2003-0P6137	W 20030516

OTHER SOURCE(S): MARPAT 140:14538

AB A method is provided for searching a substance capable of inhibiting the binding between a condensed purine derivative and pancreatic β cell or its treatment, a substance capable of inhibiting the binding between a condensed purine derivative and a protein capable of binding with the condensed purine derivative, or a substance capable of inhibiting the expression and enzymic activity of a protein capable of binding with a condensed purine derivative, wherein the use is made of a condensed purine derivative and pancreatic β cell or its treatment product, or a protein capable of binding with the condensed purine derivative

IT 254426-47-6 254426-62-5
254426-66-9 254426-67-0 254426-68-1
254426-69-2 254426-71-6 254426-72-7
254426-74-9 254426-92-1 254427-07-1
254427-15-1 254427-16-2 348149-82-6
348165-49-1 348165-85-5 348165-93-5
348166-6-6 348167-32-6 348168-39-9
349558-50-8 349559-54-0 349559-61-1
627876-22-6 627876-23-7 627876-24-8
627876-25-6 627876-26-7 627876-27-1
627876-28-2 627876-29-3 627876-30-6
627876-31-7 627876-32-8 627876-33-9
627876-34-0 627876-34-9

RL: BSB (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method for searching condensed purine derivative having antidiabetic activity)

RN 254426-47-6 CAPLUS


CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

<12/04/2007>


Erich Leese

10/513699




RN 254426-48-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 254426-62-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(2-phenylethyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 254426-66-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-2,4-dipropyl-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/513699




RN 254426-67-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopropyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254426-68-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclobutyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254426-69-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclohexyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<12/04/2007>

Erich Leese

<12/04/2007>


Erich Leese

10/513699




RN 254426-71-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(cyclopentylmethyl)-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254426-72-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-(1-methylethyl)-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 254426-74-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(1,1-dimethylethyl)-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/513699




RN 254426-92-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopropyl-1,4,7,8-tetrahydro-8-((3-methylphenyl)methyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)



RN 254427-07-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-((4-hydroxyphenyl)methyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254427-15-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(4-methyl-6-hydroxyphenyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese




RN 254427-16-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-phenyl-8-(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348149-82-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-(4-pyridinylmethyl)-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348165-49-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-(4-pyridinylmethyl)-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

<12/04/2007>


Erich Leese




RN 348165-85-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-(2-pyridinylmethyl)-, (8R)- (9CI) (CA INDEX NAME)



RN 348165-93-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-(3-pyridinylmethyl)-, (8R)- (9CI) (CA INDEX NAME)



RN 348166-06-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-(4-pyridinylmethyl)-, (8R)- (9CI) (CA INDEX NAME)




<12/04/2007>


Erich Leese

10/513699

RN 348167-32-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-(1H-1,2,4-triazol-1-ylmethyl)-, (9CI) (CA INDEX NAME)




RN 348167-33-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-(1H-pyrrol-1-ylmethyl)-, (9CI) (CA INDEX NAME)




RN 349554-63-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-2-(tetrahydro-2-furanyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 349554-73-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-(3-hydroxypropyl)-8-(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 349555-61-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-[trans-4-(aminomethyl)cyclohexyl]-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627876-22-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(phenyl-4-t-methyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627876-23-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(ethoxymethyl)-1,4,7,8-tetrahydro-4-propyl-8-(1H-pyrrol-1-ylmethyl)-, (9CI) (CA INDEX NAME)


<12/04/2007>

Erich Leese

<12/04/2007>


Erich Leese

10/513699




RN 627876-24-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-2-(tetrahydro-2H-pyran-4-yl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627876-25-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-(trans-4-hydroxycyclohexyl)-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627876-26-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-methyl-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)


10/513699

Absolute stereochemistry.




RN 627876-27-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-butyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627876-28-2 CAPLUS
 CN Benzonitrile, 4-[(4,5,7,8-tetrahydro-5-oxo-2,4-dipropyl-1H-imidazo[2,1-i]purin-8-yl)methyl]-, (8R)- (9CI) (CA INDEX NAME)



RN 627876-29-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<12/04/2007>

Erich Leese

<12/04/2007>


Erich Leese

10/513699




RN 627876-30-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(4-fluorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627876-31-7 CAPLUS
 CN Benzoic acid, 4-[(2-cyclopentyl-4,5,7,8-tetrahydro-5-oxo-4-propyl-1H-imidazo[2,1-i]purin-8-yl)methyl]-, (8R)- (9CI) (CA INDEX NAME)



RN 627876-32-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-(2-hydroxyethyl)-8-(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/513699




RN 627876-33-9 CAPLUS
 CN 1H-Imidazo[2,1-i]purin-4-(5H)-butanenitrile, 2-cyclopentyl-7,8-dihydro-5-oxo-8-(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 627876-34-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-4-(2-ethoxyethyl)-1,4,7,8-tetrahydro-8-(phenylmethyl)-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 46 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2003:931184 CAPLUS

<12/04/2007>

Erich Leese

<12/04/2007>

Erich Leese

DOCUMENT NUMBER: 140-8791
 TITLE: Therapeutic agent for diabetes
 INVENTOR(S): Nakanishi, Satoshi; Yano, Hiroshi; Mori, Kiyotoshi;
 Ogino, Juniko; Kusaka, Hideaki; Ueno, Kimihisa;
 Nomoto, Yuji; Matsuda, Yuzuru
 PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co. Ltd., Japan
 SOURCE: PCT Int. Appl., 65 pp.
 CODEN: PIXMD2

DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200309764	A1	20031127	WO 2003-JP6136	20030516
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MO, MK, MN, MM, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: OH, OM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, BY, AG, KZ, MD, RU, IS, M, AT, BE, I, NL, GR, CY, CZ, DE, DK, ES, GE, PI, PR, GB, GR, HO, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, WF, BJ, CF, CO, CI, CM, OA, ON, GO, GM, ML, MR, NE, SI, TD, TO				
AU 2003234929	A1	20031202	AU 2003-234929	20030516
JP 2002-143598	A	20020517	WO 2003-JP6136	W 20030516


PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 140-8791
 AB A therapeutic agent for diabetes, is characterized by containing at least one member selected among sulfonylurea antidiabetic agents and sulfonylurea-free K-ATP channel blocker antidiabetic agents and at least one member selected among a fused purine derivative, and pharmacol. acceptable salts of these. For example, a tablet contained glibenclamide 2, (R)-2-cyclopentyl-7,8-dihydro-8-(4-picoly)-4-propyl-1H-imidazo[2,1-i]-purin-5(4H)-one d-tartaric acid salt 18, lactose 143.4, starch 30, hydroxypropyl cellulose 6, and Mg stearate 0.6 mg.

IT 254426-47-6 348365-49-1 348362-73-2
 349554-62-7 349554-69-4 627512-37-2
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antidiabetic combinations for treatment and prevention of diabetes complications and side effects)


RN 254426-47-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348165-49-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(4-pyridinylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348362-73-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclobutyl-1,4,7,8-tetrahydro-8-(4-pyridinylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 349554-62-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclobutyl-1,4,7,8-tetrahydro-8-(4-pyridinylmethyl)-, (8R)-, (28,39)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

<12/04/2007>


Erich Leese

<12/04/2007>

Erich Leese


CM 1
 CRN 348362-73-2
 CMF C20 H24 N6 O

Absolute stereochemistry.



CM 2
 CRN 147-71-7
 CMF C4 H6 O6


Absolute stereochemistry.



RN 349554-69-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(4-pyridinylmethyl)-, (8R)-, (28,39)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1
 CRN 348165-49-1
 CMF C21 H26 N6 O


Absolute stereochemistry.



CM 2


CRN 147-71-7
 CMF C4 H6 O6

Absolute stereochemistry.



RN 627512-37-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, monohydrochloride, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



• HCl

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003-706960 CAPLUS

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese

DOCUMENT NUMBER: 139:230796
 TITLE: Synthesis of new purine derivatives
 INVENTOR(S): Miyamoto, Kenichi; Sawanishi, Hiroaki; Suzuki, Koichi; Yamamoto, Manabu; Shimura, Susumu
 PATENT ASSIGNEE(S): Lotte Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
 CODEN: JXKXAF

DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003252875	A	20030910	JP 2002-58098	20020304
KR 2003072251	A	20030913	KR 2003-13401	20030304
PRIORITY APPLN. INFO.:			JP 2002-58098	A 20020304
OTHER SOURCE(S): MARPAT 139:230796 G1				




AB The patent relates to the preparation of purine derivs. and salts for pharmaceutical uses such as PDE IV isoenzyme inhibitor. The purine derivs. have the following formula (I) wherein R1, R2, R3 are hydrogen, or hydroxy, low alkoxy, acyl substituted C1-C6 alkyl, or phenyl; and R4, and R5 are independently hydroxy, low alkoxy, acyl substituted C1-C6 alkyl, or Ph group; and pharmaceutically compatible salts. The purine derivs. and pharmaceutically compatible salts may have the following formula (II) wherein R1, R2 are hydrogen, or hydroxy, low alkoxy, acyl substituted C1-C6 alkyl, or phenyl, and n = 2 or 3. Thus, 8-methyl-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]purin-5-one prepared from 6-[(2-hydroxy-1-methyl)ethyl]amino-3-propylpurine-2-one in presence of triethylamine, and methanesulfonyl chloride was evaluated for PDE I test and gave greater activity than the control using Denoufylline.

IT 594853-12-0 594853-14-2P
 RL: BPN (Synthetic preparation); PREP (Preparation)
 (preparation of new purine derivs.)


RN 594853-12-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-methyl-4-phenyl- (9CI)
 (CA INDEX NAME)



RN 594853-14-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-7-methyl-4-phenyl- (9CI)
 (CA INDEX NAME)



IT 492439-17-5P 492439-21-1P 492439-95-9P
 492439-96-0P 594853-03-9P 594853-05-1P
 RL: BSU (Biological study, unclassified); BPN (Synthetic preparation);
 BTOL (Biological study); PREP (Preparation)
 (synthesis of new purine derivs.)
 RN 492439-17-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-methyl-1,4-dipropyl- (9CI) (CA INDEX NAME)




RN 492439-21-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-7-methyl-1,4-dipropyl- (9CI) (CA INDEX NAME)

<12/04/2007>


Erich Leese

<12/04/2007>


Erich Leese




RN 492439-95-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-methyl-4-propyl- (9CI)
 (CA INDEX NAME)




RN 492439-96-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-7-methyl-4-propyl- (9CI)
 (CA INDEX NAME)



RN 594853-03-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-8-methyl-3,4-dipropyl- (9CI) (CA INDEX NAME)



RN 594853-05-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-7-methyl-3,4-dipropyl- (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 46 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2003:670403 CAPLUS
 139:375476
 DOCUMENT NUMBER:
 TITLE:
 AUTHOR(S):

Prostaglandin E2-mediated anabolic effect of a novel inhibitor of phosphodiesterase 4. XT-611, in the in vitro bone marrow culture
 Miyamoto, Ken-Ichi; Suzuki, Hirokazu; Yamamoto, Shinya; Saitoh, Yukie; Ochiai, Eiji; Moritani, Shuzo; Yokogawa, Koichi; Waki, Yoshihiro; Kasugai, Shiohei; Kanazawa, Hiroaki; Yamagami, Hideomi

CORPORATE SOURCE: Department of Hospital Pharmacy, School of Medicine, Kanazawa University, Kanazawa, Japan
 SOURCE: Journal of Bone and Mineral Research (2003), 18(6), 1471-1477

CODEN: JBMREJ, ISBN: 0884-0431
 American Society for Bone and Mineral Research

JOURNAL: English

AB The mechanism of osteoblast formation by a novel PDE4 inhibitor, XT-611, was studied in the in vitro bone marrow culture system. The compound potentiated the osteoblast differentiation through accumulation of cAMP after autocrine stimulation of EP4 receptor by PGE2 in pro-osteoblastic cells. Introduction: We previously reported that inhibitors of phosphodiesterase (PDE4) isoenzyme increase osteoblast formation in an in vitro bone marrow culture system and inhibit bone loss in animal osteoporosis models. Here we investigated the mechanism of the effect of a novel PDE4 inhibitor, 3,4-dipropyl-4,5,7,8-tetrahydro-3H-imidazo[1,2-i]purin-5-one (XT-611). On osteoblast formation in the in vitro bone marrow culture system, Materials and Methods. The bone marrow cell were cultured in the presence of 0.2 nM ascorbic acid phosphate ester, 1 mM β -glycerophosphate, and 10 nM dexamethasone for 10 days. Drug treatments were done for 24 h on day 3 of culture. Results: PDE4 inhibitors, including XT-611 but not PDE3 and PDE5 inhibitors, increased mineralized nodule formation in rat and mouse bone marrow cell cultures. During culture of the bone marrow cells, prostaglandin E2 (PGE2) production increased with a peak on day 4, but the increase was completely inhibited by indomethacin, an unselective cyclo-oxygenase (COX) inhibitor. Spontaneous and XT-611-induced mineralized-nodule formation was also inhibited by indomethacin and COX-2 inhibitors, in a similar potential. Alkaline phosphatase-positive nodule formation in the absence or presence of XT-611 was inhibited by an antagonist of EP4 receptor, AM23848B, and synergistically potentiated by 1 α -deoxy-PGE1, but it was not influenced by other EP antagonists and agonists examined. The expression of PDE4 and EN mRNAs was observed in bone marrow cells. The effect of XT-611 was also confirmed to involve an increase of cAMP and the cAMP-dependent protein kinase pathway. Conclusion: These results suggest that PDE4 stimulates

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese

differentiation of osteoblast progenitor cells through the EP4 receptor in an autocrine manner, and the PDE4 inhibitor potentiates the differentiation by inhibiting hydrolysis of cAMP in the cells.

IT 195869-73-9, XT-611
RL: BDU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(PGE2-mediated anabolic effect of a novel inhibitor of phosphodiesterase 4. XT-611, in bone marrow culture)

RN 195869-73-9 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-3,4-dipropyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:669208 CAPLUS
DOCUMENT NUMBER: 140:87630
TITLE: Inhibition of osteoclastogenesis by a phosphodiesterase 4 inhibitor XT-611 through synergistic action with endogenous prostaglandin E2
AUTHOR(S): Yamagami, Hidemori; Nishioka, Tatsuo; Ochiai, Eiji; Fukushima, Kazuyoshi; Nomura, Masaaki; Kasugai, Shiohei; Moritani, Shuzo; Yokogawa, Koichi; Miyamoto, Ken-ichi
CORPORATE SOURCE: School of Medicine, Department of Hospital Pharmacy, Kanazawa University, Kanazawa, 920-8641, Japan
SOURCE: Biochemical Pharmacology (2003), 66(5), 801-807
PUBLISHER: CODEN: BCPMA6; ISSN: 0006-2952
DOCUMENT TYPE: Elsevier Science B.V.
LANGUAGE: English
AB We examined the effect of a phosphodiesterase 4 (PDE4) inhibitor, 3,4-dipropyl-4,5,7,8-tetrahydro-3H-imidazo[2,1-i]purin-5-one (XT-611) on osteoclast formation in three different mouse bone marrow cell (BMC) culture systems. We confirmed that selective inhibitors of PDE4, including XT-611, among several PDE inhibitors decreased osteoclast formation in the BMC culture system. XT-611 also inhibited osteoclast formation in co-culture of mouse bone marrow stromal cell line ST2 and adherent cell-depleted (ACD)-BMCs. However, it did not inhibit osteoclastogenesis in culture of ACD-BMCs alone in the presence of macrophage-colony stimulating factor (M-CSF) and soluble receptor activator of NF- κ B ligand (sRANKL). XT-611 significantly increased prostaglandin E2 (PGE2) production from ST2 cells and, in combination with PGE2, synergistically increased cAMP concentration in osteoclast progenitors.


In the ST2 co-culture system, XT-611 did not influence the expression of RANKL, osteoprotegerin and RANK mRNA. By combined treatment with XT-611 and PGE2 of ACD-BMCs, osteoclast multinucleation was clearly inhibited

<12/04/2007>

Erich Leese


with decrease in the expression of calcitonin receptor mRNA, while the expression of RANK and c-fms (an M-CSF receptor) mRNAs was unchanged. These results indicate that the PDE4 inhibitor inhibits osteoclastogenesis by acting on osteoclast progenitors synergistically with PGE2 secreted from stromal cells, but not by influencing the cell-to-cell interaction between stromal cells and osteoclast progenitors.

IT 195869-73-9, XT-611
RL: BDU (Biological study, unclassified); DMA (Drug mechanism of action); PAC (Pharmacological activity); BIOL (Biological study); (Inhibition of osteoclastogenesis by PDE4 inhibitor XT-611 synergized with endogenous PGE2)
RN 195869-73-9 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-3,4-dipropyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:416529 CAPLUS
DOCUMENT NUMBER: 139:230506
TITLE: Improved, efficient synthesis for multigram-scale production of PSS-10, a potent antagonist at human A3 adenosine receptors
AUTHOR(S): Burbiel, Joachim; Thorand, Mark; Muller, Christa E.
CORPORATE SOURCE: Pharmazeutisches Institut, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, D-53115, Germany
SOURCE: Heterocycles (2003), 60(6), 1425-1432
PUBLISHER: CODEN: HETCYAM; ISSN: 0385-5114
DOCUMENT TYPE: Japan Institute of Heterocyclic Chemistry
LANGUAGE: English
OTHER SOURCE(S): Journal
GI CASREACT 139:230506



<12/04/2007>

Erich Leese


10/513699

10/513699

AB The reported synthesis of PSS-10 [*8*-ethyl-4-methyl-2-(2,3,5-trichlorophenyl)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]purin-5-one (I)], a potent A3-selective adenosine receptor antagonist, gives only moderate yields and is not suitable for the production of I on a multi-gram scale. Attempts to develop alternative routes and an improved procedure suitable for preparing large quantities of I, required for pharmacological studies, are described.


IT 439902-54-2P
RL: PNU (Preparation, unclassified); PREP (Preparation)
(PSS-10; multigram-scale production of PSS-10 useful as a potent antagonist at human A3 adenosine receptors)
RN 439902-54-2 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-4-methyl-2-(2,3,5-trichlorophenyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 591771-91-4P, PSS 10 hydrochloride
RL: SPN (Synthetic preparation); PREP (Preparation)
(multigram-scale production of PSS-10 useful as a potent antagonist at human A3 adenosine receptors)
RN 591771-91-4 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-4-methyl-2-(2,3,5-trichlorophenyl)-, monohydrochloride, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:329690 CAPLUS
DOCUMENT NUMBER: 139:128160
TITLE: Identification of essential residues involved in the allosteric modulation of the human A3 adenosine receptor
AUTHOR(S): Gao, Zhan-Guo; Kim, Soo-Kyung; Gross, Ariel S.; Chen, Aishe; Blaustein, Joshua B.; Jacobson, Kenneth A.
CORPORATE SOURCE: Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Department of Health and Human Services, National Institutes of Health, Bethesda, MD, USA
SOURCE: Molecular Pharmacology (2003), 63(5), 1021-1031
PUBLISHER: CODEN: MOPMA3; ISSN: 0026-8951
DOCUMENT TYPE: American Society for Pharmacology and Experimental Therapeutics
LANGUAGE: Journal
AB The authors examined the effects on allosteric modulation and ligand binding of the mutation of amino acid residues of the human A3 adenosine receptor (AAr3) that are hypothesized to be near one of three loci: the putative sodium binding site, the putative ligand binding site, and the DRY motif in transmembrane helical domain 3. The effects of three heterocyclic allosteric modulators (the imidazoquinolin-2-cyclopentyl-4-phenylamino-1H-imidazo[4,5-c]quinolin-4-methoxy-N-[7-methyl-3-(2-pyridinyl)-1-isoquinolinal]benzamide (VUP5455), and the amiloride analog 5-(N,N-hexamethylene)-amiloride) on the dissociation of the agonist radioligand, N6-(4-amino-3-[125I]iodobenzyl)-5'-N-methylcarboxamidoadenosine, were compared at wild-type (WT) and mutant AAr3. The P182A3.43 and Q274A7.45 mutations affected the allosteric effects of all three modulators but had little effect on agonist binding. The N30A1.50 and D58N2.50 mutations abolished the allosteric effects of DU124183 and VUP5455, but not HMA, whereas the D107N3.49 mutation abolished the effects of DU124183, but not HMA or VUP5455. The T94A3.36,

<12/04/2007>

Erich Leese

<12/04/2007>

Erich Leese

H95A3.37, K152AEL2, W243A6.48, L244A6.52 mutations did not influence allosteric effects of the modulators. Sodium ions (100 mM), which modulated agonist binding at a variety of receptors, caused an approximately 5-fold increase in agonist binding at WT A3ARs, but did not show any effect on D50A1.50, D107N3.49, and F192A6.43 mutant receptors. In contrast, NaCl induced a modest increase of agonist binding in N30A1.50 and N274A7.45 mutant receptors. NaCl decreased the dissociation rate of the antagonist radioligand [³H]-ethyl-4-methyl-2-phenyl-[8R]-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]purin-5-one (PSB-11) at the WT A3ARs, but not the D50N2.50 mutant receptor. The results were interpreted using a rhodopsin-based mol. model of the A3AR to suggest multiple binding modes of the allosteric modulators.


IT 444717-56-0, PSB-11

RL: B9U (Biological study, unclassified); BIOL (Biological study) (essential residues involved in allosteric modulation and agonist binding of human A3 adenosine receptor)

RN 444717-56-0, CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-4-methyl-2-phenyl-, (8R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 46 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2003221519 CAPLUS

DOCUMENT NUMBER: 138:231748

TITLE: Methods using adenosine A1 receptor antagonists for treating pulmonary disease

INVENTOR(S): Smith, Glenn J.; Spinali, Francis G.

PATENT ASSIGNEE(S): Biogen, Inc., USA; Musc Foundation for Research Development

SOURCE: PCT Int Appl., 81 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022284	A1	20030320	WO 2002-U328580	20020906
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BO, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PH,				

<12/04/2007>

Erich Leese

PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VC, VN, YU, ZA, ZM, ZW, RW: GH, GM, KB, LG, MM, MZ, SD, SL, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BA, CF, CG, CI, CM, GA, GN, QO, GW, ML, MR, NE, SN, TD, TO

CA 2459513 A1 20010320 CA 2002-2459513 20020906

AU 2002341618 A1 20030324 AU 2002-341618 20020906

EP 1429775 A1 20040623 EP 2002-775769 20020906

R: AT, BE, CH, DE, DK, ES, FR, OB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, BE, SK

BE 2002012329 A 20040921 BE 2002-12329 20020906

HU 200401805 A2 20041228 HU 2004-1805 20020906

HU 200401805 A3 20070502 20020906

CH 1564688 A 20050112 CH 2002-819526 20020906

JP 2005019195 T 20050120 JP 2003-526413 20020906

NZ 532083 A 20051028 NZ 2002-532083 20020906

IN 2004KN00276 A 20060331 IN 2004-KN276 20040301

ZA 2004001765 A 20050405 ZA 2004-1765 20040303

NO 2004000982 A 20040603 NO 2004-982 20040305

US 2004259885 A1 20041223 US 2004-488573 20040317

PRIORITY APPLN. INFO.: US 2001-317908P P 20010906

WO 2002-U328580 W 2002-0328580 20020906

OTHER SOURCE(S): MARDAT 138:231748

AB Methods useful for reducing pulmonary vasoconstriction or improving pulmonary hemodynamics in a patient are disclosed. More particularly, the invention discloses administering adenosine A1 receptor antagonists to reduce pulmonary vasoconstriction and improve pulmonary hemodynamics.

IT 14974-78-5 501667-79-4 501667-80-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (adenosine A1 receptor antagonists for treating pulmonary disease)

RN 14974-78-5 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-2-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




RN 501667-79-4 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-8-(1-methylethyl)-4-propyl- (9CI) (CA INDEX NAME)


<12/04/2007>

Erich Leese

<12/04/2007> Erich Leese



RN 501667-80-7 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-4-propyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 46 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 20037897 CAPLUS

DOCUMENT NUMBER: 139:30163

TITLE: 2-Phenylimidazo[2,1-i]purin-5-ones: Structure-Activity Relationships and characterization of potent and selective inverse agonists at Human A3 adenosine receptors

AUTHOR(S): Ozol, Vita; Thorand, Mark; Diekmann, Martina; Qurashi, Ramatullah; Schumacher, Britta; Jacobson, Kenneth A.; Muller, Christa E.

CORPORATE SOURCE: University of Bonn, Pharmaceutical Institute

SOURCE: Poppeldorf, Bonn, D-53115, Germany
Biorganic & Medicinal Chemistry (2003), 11(3), 347-356

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:30163

AB Structure-activity relationships of 2-phenyl-imidazo[2,1-i]purin-5-ones as ligands for human A3 adenosine receptors (A3Rs) were investigated. An Et group in the 8-position of the imidazoline ring of 4-methyl-2-phenyl-imidazopurinone leading to chiral compds. was found to increase affinity for human A3 ARs by several thousand-fold. Pr substitution instead of Me at N4 decreased A3 affinity but increased A1 affinity leading to potent A1-selective AR antagonists. The most potent A1 antagonist of the present series was (8S)-ethyl-2-phenyl-4-propyl-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]purin-5-one exhibiting a Ki value of 1 nM at rat A1 ARs and greater than 100-fold selectivity vs. rat A2A and human A1 ARs. At human A1 ARs 2-phenylimidazo[2,1-i]purin-5-ones were generally less potent and therefore less A1-selective (K_i: 3, Ki: 98 nM), 2-, 3-, or 4-mono-chlorination of the 2-Ph ring reduced A3 affinity but led to an increase in affinity for A1 ARs, whereas di- (3,4-dichloro) or polychlorination (2,3,5-trichloro) increased A3 affinity. The most potent and selective A3 antagonist of the present series was the trichlorophenyl derivative (R)-8-ethyl-4-methyl-2-(2,3,5-trichlorophenyl)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]purin-5-one exhibiting a subnanomolar Ki value at human A3 ARs and greater than 800-fold selectivity vs. the other AR subtypes. Methylation of 4-alkyl-2-phenyl-substituted imidazo[2,1-i]purin-5-ones led exclusively to the N9-Me derivs., which exhibited largely reduced AR affinities as compared to the unmethylated compds. [35S]GTPyS binding studies of the most potent 2-phenyl-imidazo[2,1-i]purin-5-ones at membranes of Chinese hamster ovary cells expressing the human A3 AR revealed that the compds. were inverse agonists at A3 receptors under standard test conditions. Due to their high A3 affinity, selectivity, and relative high water-solubility, 2-phenyl-imidazo[2,1-i]purin-5-ones may become useful research tools.


IT 439902-54-2P 543699-94-1

RL: PAC (Pharmacological activity); RCT (Reactant); BPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (structure-activity of 2-phenylimidazo[2,1-i]purin-5-ones as inverse agonists of human A3 adenosine receptor).

RN 439902-54-2 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-4-methyl-2-(2,3,5-trichlorophenyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 543699-94-1 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-(3,4-dichlorophenyl)-8-ethyl-1,4,7,8-

<12/04/2007>


Erich Leese

<12/04/2007> Erich Leese

10/513699

tetrahydro-4-propyl-. (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 444717-56-0P 543699-91-8P 543699-92-9P

543699-93-0P 543699-95-2P 543699-96-1P

543699-97-4P


RL: PAC (Pharmacological activity); BPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(structure-activity of 2-phenylimidazo[2,1-i]purin-5-ones as inverse agonists of human A3 adenosine receptor)

RN 444717-56-0 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-4-methyl-2-phenyl-, (8S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 543699-91-8 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-4-methyl-2-phenyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<12/04/2007>

Erich Leese

<12/04/2007>

Erich Leese


10/513699



RN 543699-96-3 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 2-(3-chlorophenyl)-8-ethyl-1,4,7,8-tetrahydro-4-methyl-, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 543699-97-4 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 2-(4-chlorophenyl)-8-ethyl-1,4,7,8-tetrahydro-4-methyl-, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT:


29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/513699



RN 543699-92-9 CAPLUS


CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-4-methyl-2-phenyl-, (9CI) (CA INDEX NAME)



RN 543699-93-0 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-2-phenyl-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 543699-95-2 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 2-(2-chlorophenyl)-8-ethyl-1,4,7,8-tetrahydro-4-methyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/513699

LA ANSWER 23 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002-723414 CAPLUS
 DOCUMENT NUMBER: 138:137075
 TITLE: Synthesis and cyclic AMP phosphodiesterase 4 isoenzyme inhibitory activity of heterocycle condensed purines
 AUTHOR(S): Suzuki, Hirotazu; Yamamoto, Manabu; Shimura, Susumu; Miyamoto, Ken-ichi; Yamamoto, Kenji; Sawanishi, Hiroyuki
 CORPORATE SOURCE: Department of Synthetic Chemistry, Hokuriku University, Kanazawa, 920-1181, Japan
 SOURCE: Chemical & Pharmaceutical Bulletin (2002), 50(9), 1163-1168
 CODEN: CPBTAL; ISSN: 0009-2363
 PUBLISHER: Pharmaceutical Society of Japan
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 138:137075
 GI



AB To reverse the adverse reactions of alkylxanthines and to develop novel inhibitors of cAMP phosphodiesterase 4 (PDE4), a series of heterocycle [a]-, [b]-, [c,d]-, and [d]-condensed purines were designed and synthesized. Although all compds. did not display PDE4 and PDE3 inhibitory activities, several heterocycle [d]-condensed purines strongly inhibited PDE4, specifically, 1-[1-(4-chlorophenyl)-8-ethyl-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]purin-5-one] (I), exhibited comparable PDE4 inhibitory activity (IC50=1.9 μM) to rolipram and domperidone (DBP).


IT 492439-95-9P 492439-96-0P
 RL: PAC (Pharmacological activity); RCT (Reactant); BPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of heterocycle condensed purines from purine and pyrimidine derivs. and their activity as cAMP phosphodiesterase 4 isoenzyme inhibitors)
 RN 492439-95-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-methyl-4-propyl- (9CI) (CA INDEX NAME)

<12/04/2007>


Erich Leese

<12/04/2007>


Erich Leese




RN 492439-96-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-7-methyl-4-propyl- (9CI)
 (CA INDEX NAME)



IT 492439-17-5P 492439-21-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of heterocycle condensed purines from purine and pyrimidine derivs. and their activity as cAMP phosphodiesterase 4 isoenzyme inhibitors)
 RN 492439-17-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-methyl-1,4-dipropyl- (9CI) (CA INDEX NAME)



RN 492439-21-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-7-methyl-1,4-dipropyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:575737 CAPLUS
 DOCUMENT NUMBER: 137:135504
 TITLE: Methods of inducing ovulation by administering a non-polypeptide cAMP level modulator
 INVENTOR(S): Palmer, Stephen; McKenna, Sean; Tepper, Mark; Eshkol, Aliza; MacNamee, Michael C.
 PATENT ASSIGNEE(S): Applied Research Systems Holding N.V., USA
 SOURCE: U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of U.S. Ser. No. 928,268.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002103106	A1	20020801	US 2001-14812	20011214
US 6953774	B2	20051011		
US 2002065324	A1	20020530	US 2001-928268	20010810
CA 246939	A1	20030626	CA 2001-246939	20011214
AU 2002217111	A1	20030630	AU 2002-217111	20011214
EP 1463494	A1	20030606	EP 2001-274987	20011214
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, LI, LU, NL, SE, MC, PT, BE, SI, LT, LV, FI, RO, MT, CY, AL, TR			
BR 2003017298	BR	20040126	BR 2001-17198	20011214
CN 1582146	A	20050216	CN 2001-823951	20011214
JP 2005516924	T	20050609	JP 2001-552277	20011214
US 2005148501	A1	20050707	US 2001-498639	20011214
US 2006003925	A1	20060105	US 2005-169183	20050628
US 7078216	B2	20060718		
US 2006293222	A1	20061228	US 2006-456033	20060706
PRIORITY APPLN. INFO.:			US 2000-224962P	P 20000811
			US 2001-928268	A2 20010810
			US 2001-14812	A3 20011214
			WO 2001-EP14730	W 20011214
			US 2005-169183	A2 20050628

AB The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cAMP level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulator include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms. Pharmaceutical compns. containing


<12/04/2007>

Erich Leese

<12/04/2007>


Erich Leese

the cAMP modulators are also claimed.
 IT 195869-73-9
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methods of inducing ovulation by administering a non-polypeptide cAMP level modulator)
 RN 195869-73-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-3,4-dipropyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:445206 CAPLUS
 DOCUMENT NUMBER: 137:201379
 TITLE: Imidazo[2,1-i]purin-5-ones and Related Tricyclic Water-Soluble Purine Derivatives: Potent A2A- and A3-Adenosine Receptor Antagonists
 AUTHOR(S): Mueller, Christa E.; Thorand, Mark; Ourishi, Ramatullah; Diekmann, Martina; Jacobson, Kenneth A.; Padgett, William L.; Daly, John W.
 CORPORATE SOURCE: Pharmaceutical Institute Poppelsdorf, University of Bonn, Bonn, Germany
 SOURCE: Journal of Medicinal Chemistry (2002), 45(16), 3440-3450
 PUBLISHER: JMCMAR; ISSN: 0022-2623
 CODEN: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:201279
 GI




AB A series of tricyclic imidazo[2,1-i]purinones I (R1, R4 = H, Me; R2 = H,

Et, (E)-PhCH:CH; R3 = H, Me, PhCH2; R5 = H, Me, Et) and ring-enlarged analogs, e.g., II, derived from xanthine derivs. were prepared as adenosine receptor (AR) antagonists. In comparison with xanthine, these tricyclic compds. exhibited increased water solubility due to a basic nitrogen atom, which can be protonated under physiol. conditions. A new capillary electrophoresis method was developed for the determination of the enantiomeric purity of selected chiral products using native and modified β -cyclodextrins as chiral discriminators. The compds. were investigated in radioligand binding assays at rat brain A1 and A2 ARs. Selected I were addnl. investigated in radioligand binding assays at human recombinant A3 ARs and in functional studies (adenylate cyclase assays) at A1 ARs of rat fat cell membranes, A2A ARs of rat PC 12 cell membranes, and mouse A2B ARs of NIH 3T3 cell membranes, and showed the structure-activity relationships similar to those of the corresponding xanthine derivs. The 2-styrylimidazopurinones I (R1 = H, Me; R2 = (E)-PhCH:CH; R3 = H; R4 = H, Me; R5 = Et) were less potent at A2A ARs as compared to 8-styrylxanthine derivs. The most potent compound at A2A ARs was (S)-I (R1 = R3 = Me, R2 = (E)-PhCH:CH; R4 = H, R5 = Et, (III)) exhibiting a Ki value of 424 nM at rat A2B ARs. III was also highly selective for A2A receptors vs A1 and A3 ARs; however, the selectivity vs A2B ARs was low. Among the 1-unsubstituted (2-phenyl)imidazopurinones, the most potent A3 antagonist was (R)-I (R1 = R4 = H, Me; Ph, R2 = Me, R3 = Et) exhibiting a Ki value of 2.2 nM with selectivity for A3 receptors vs all other AR subtypes. I 453591-46-3P 453591-57-6P

RL: ANT (Analyte); PAC (Pharmacological activity); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation)
 (preparation of water soluble imidazopurinones and ring-enlarged analogs as adenosine receptor antagonists)

RN 453591-46-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-4-methyl-2-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



• HCl

RN 453591-57-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-4-methyl-2-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)


<12/04/2007>

Erich Leese

<12/04/2007>

Erich Leese

10/513699



● HCl

IT 453591-41-8P 453591-42-9P 453591-43-0P

453591-44-1P 453591-45-2P 453591-47-4P

453591-48-5P 453591-49-6P 453591-50-9P

453591-51-0P 453591-52-1P 453591-53-2P

453591-54-3P 453591-55-4P 453591-56-5P

453591-58-7P 453591-59-8P 453591-60-1P

453591-61-2P 453591-62-3P 453591-63-4P


453591-64-5P 453591-65-6P 453591-66-7P

453591-67-8P

RL: PAC (Pharmacological activity), SPPN (Synthetic preparation); BIOL (Biological study); PPREP (Preparation) (preparation of water soluble imidazopurinones and ring-enlarged analogs as adenosine receptor antagonists)

RN 453591-41-8 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 453591-42-9 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-1-methyl-4-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)


10/513699



● 2 HCl

RN 453591-43-0 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-1,4-dimethyl-, dihydrochloride, (9CI) (CA INDEX NAME)




● 2 HCl

RN 453591-44-1 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-1,4,8-trimethyl-, dihydrochloride, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

<12/04/2007>

Erich Leese

<12/04/2007>


Erich Leese

10/513699

RN 453591-45-2 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-1,4,8-trimethyl-, dihydrochloride, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 453591-47-4 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-1,4-dimethyl-, dihydrochloride, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 453591-48-5 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-1,4-dimethyl-, dihydrochloride, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/513699



● 2 HCl

RN 453591-49-6 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-1,4,7-trimethyl-, dihydrochloride, (9CI) (CA INDEX NAME)




● 2 HCl

RN 453591-50-9 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-1,4,7-trimethyl-, dihydrochloride, (7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese

10/513699


RN 453591-51-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-1,4,7-trimethyl-,
 dihydrochloride, (7S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl


RN 453591-52-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-1-methyl-2-phenyl-,
 monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 453591-53-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-1,4-dimethyl-2-phenyl-,
 monohydrochloride (9CI) (CA INDEX NAME)

10/513699



● HCl


RN 453591-54-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-1,4-dimethyl-2-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 453591-55-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-1,4-dimethyl-2-phenyl-, monohydrochloride, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese

10/513699

RN 453591-56-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-1,4-dimethyl-2-phenyl-, monohydrochloride, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 453591-58-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-4-methyl-2-phenyl-, monohydrochloride, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 453591-59-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-4-methyl-2-phenyl-, monohydrochloride, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/513699




● HCl

RN 453591-60-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-1,4-dimethyl-2-[(1E)-2-phenylethienyl]-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 453591-61-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-1,4-dimethyl-2-[(1B)-2-phenylethienyl]-, (8B)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

RN 453591-62-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-4-methyl-2-[(1E)-

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese

10/513699

2-phenylethynyl-, monohydrochloride, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 453591-63-4 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-4-methyl-2-[(1E)-2-phenylethynyl]-, monohydrochloride, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



● HCl


RN 453591-64-5 CAPLUS
CN Pyrimido[2,1-i]purin-5(1H)-one, 4,7,8,9-tetrahydro-1,4-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)

10/513699




● 2 HCl

RN 453591-65-6 CAPLUS
CN Pyrimido[2,1-i]purin-5(1H)-one, 2-chloro-4,7,8,9-tetrahydro-1,4-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 453591-66-7 CAPLUS
CN 5H-[1,3]Diazepino[2,1-i]purin-5-one, 1,4,7,8,9,10-hexahydro-1,4-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 453591-67-8 CAPLUS
CN [1,3]Diazocino[2,1-i]purin-5(1H)-one, 4,7,8,9,10,11-hexahydro-1,4-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)


<12/04/2007>

Erich Leese

<12/04/2007>

Erich Leese

10/513699



● 2 HCl

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 46 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2002471672 CAPLUS

DOCUMENT NUMBER: 138:19249

TITLE: Selective phosphodiesterase type 4 inhibitors reduce the prolonged survival of eosinophils stimulated by granulocyte-macrophage colony-stimulating factor

AUTHOR(S): Takeuchi, Masayuki; Tatsumi, Yasushi; Kitachi, Kiyoyuki; Baba, Kenji; Suzuki, Ryujiro; Shibata, Eiji; Takagi, Kenji; Miyamoto, Ken-ichi; Hasegawa, Takasaki, Takagi, Kenzo

CORPORATE SOURCE: Second Department of Internal Medicine and Laboratory Medicine, Nagoya University School of Medicine, Nagoya, 466-8560, Japan

SOURCE: Biological & Pharmaceutical Bulletin (2002); 25(2), 184-187

CODEN: BPBLEO; ISSN: 0918-6158

PUBLISHER: Pharmaceutical Society of Japan

DOCUMENT TYPE: Journal


LANGUAGE: English

AB It is well known that bronchial asthma is defined as chronic eosinophilic inflammation of the respiratory tract and that as one of the various types of inflammatory cells, eosinophils induce the airway inflammation of chronic asthma. Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been shown to play an important role in the prolongation of the survival of eosinophils. We investigated the inhibitory effect of the selective phosphodiesterase (PDE) 4 inhibitors, 3,4-dipropyl-4,5,7,8-tetrahydro-3H-imidazo[2,1-i]purin-5-one (XT-611) and rolipram, and the nonselective PDE inhibitor theophylline, against GM-CSF-induced prolongation of the survival of eosinophils isolated from patients with bronchial asthma. Eosinophils (106 cells/mL) were incubated in the presence of GM-CSF together with or without theophylline, rolipram or XT-611 at 37, and the viable cells were assessed up to 4d using Trypan blue dye exclusion. The presence of theophylline (10-4 M), rolipram (10-4-10-5 M) or XT-611 (10-4-10-5 M) significantly reduced the GM-CSF (10 pg/mL)-induced prolongation of viability of eosinophils. These findings suggest that selective PDE 4 inhibitors, including XT-611, may effectively reduce the activities of inflammatory cells in the airway of bronchial asthma patients.

10/513699

IT 195869-73-9, XT-611
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); US88 (Uses)
(PDE4 inhibitors reduce the prolonged survival of eosinophils stimulated by granulocyte-macrophage colony-stimulating factor)

RN 195869-73-9 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-3,4-dipropyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 46 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2002440202 CAPLUS

DOCUMENT NUMBER: 138:93217

TITLE: KP26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one) hydrochloride, a new potent and selective adenosine A3 receptor antagonist

AUTHOR(S): Saki, Mayumi; Tsumuki, Hiroshi; Nonaka, Hiromi; Shinoda, Junichi; Ichimura, Michio

CORPORATE SOURCE: Kyowa Hakko Kogyo Co., Ltd., Pharmaceutical Research Institute, Sunto-gun, Shizuoka, Nagazumi-cho, 411-8731, Japan

SOURCE: European Journal of Pharmacology (2002), 444(3), 133-141

CODEN: EJPBHAZ; ISSN: 0014-2999

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The authors investigated the biochemical and pharmacological properties of a new adenosine A3 receptor antagonist, KP26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one hydrochloride). This compound was characterized using [¹²⁵I]AB-MECA or [³⁵S]guanosine 5'-O-(3'-thiophotophosphate) (GTPyS) binding to membranes from human embryonic kidney 293 (HEK293) cells expressing human adenosine A3 receptors. KP26777 showed a K_i value of 0.29±0.03 nM for human adenosine A3 receptors labeled with [¹²⁵I]AB-MECA and possessed 9000-, 2350- and 3100-fold selectivity vs. human adenosine A1, A2A and A2B receptors, resp. The inhibitory mode of binding was competitive. KP26777 inhibited the binding of [³⁵S]GTPyS stimulated by 1 μM 2-chloro-N6-(4-iodobenzyl)adenosine-5'-N-methyluronamide (C1-IB-MECA). The IC₅₀ value was 270±65 nM; the compound had no effect on basal activity. Dexamethasone treatment for HL-60 cells, human promyelocytic leukemia, up-regulated functional adenosine A3 receptor expression, and resulted in the enhanced elevation of intracellular Ca²⁺ concentration ([Ca²⁺]_i) via the adenosine A3 receptor. KP26777 antagonized this [Ca²⁺]_i mobilization induced by C1-IB-MECA, with a K_B value of 0.43±0.14 nM. These results

<12/04/2007>

Erich Leese

<12/04/2007>


Erich Leese

10/513699




RN 433246-63-0 CAPLUS
 CN Bicyclo[2.2.2]octane-1-propanoic acid, 4-[(*S*R)-4,5,7,8-tetrahydro-8-(1-methylethyl)-5-oxo-4-propyl-1*H*-imidazo[2,1-*i*]purin-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 433246-68-5 CAPLUS
 CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[(4,5,7,8-tetrahydro-5-oxo-4-propyl-1*H*-imidazo[2,1-*i*]purin-2-yl)- (9CI) (CA INDEX NAME)

10/513699



RN 433246-74-3 CAPLUS
 CN Bicyclo[2.2.2]octane-1-propanoic acid, 4-[(*S*R)-4,5,7,8-tetrahydro-8-methyl-5-oxo-4-propyl-1*H*-imidazo[2,1-*i*]purin-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 433246-81-2 CAPLUS
 CN 5*H*-Imidazo[2,1-*i*]purin-5-one, 1,4,7,8-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-8-(1-methylpropyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<12/04/2007>

Erich Leese

<12/04/2007>


Erich Leese

10/513699



RN 433246-85-6 CAPLUS
 CN 5*H*-Imidazo[2,1-*i*]purin-5-one, 2-bicyclo[2.2.2]oct-1-yl-8-ethyl-1,4,7,8-tetrahydro-4-propyl-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 433246-91-4 CAPLUS
 CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[(*S*R)-8-ethyl-4,5,7,8-tetrahydro-5-oxo-4-propyl-3*H*-imidazo[2,1-*i*]purin-2-yl]- (CA INDEX NAME)


Absolute stereochemistry.

10/513699



RN 433246-97-0 CAPLUS
 CN 5*H*-Imidazo[2,1-*i*]purin-5-one, 3,4,7,8-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-4,8-dipropyl-, (8R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433247-03-1 CAPLUS
 CN 5*H*-Imidazo[2,1-*i*]purin-5-one, 3,4,7,8-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-7-methyl-4-propyl-, (7S)- (CA INDEX NAME)


Absolute Stereochemistry.

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese




RN 433247-09-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-8-phenyl-4-propyl-, (8R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433247-19-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-8-((18)-1-methylpropyl)-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 433247-14-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-7-methyl-4-propyl-, (7R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433247-25-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-(1,1-dimethylethyl)-3,4,7,8-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-4-propyl-, (8R)- (CA INDEX NAME)


Absolute stereochemistry.

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese




RN 433247-31-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-8-(2-methylpropyl)-4-propyl-, (8R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433247-45-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-butyl-1,4,7,8-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 433247-37-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-8-(phenylmethyl)-4-propyl-, (8R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433247-52-0 CAPLUS
 CN Pyrimido[2,1-i]purin-5(1H)-one, 4,7,8,9-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-4-propyl- (9CI) (CA INDEX NAME)


<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese

10/513699




RN 433247-58-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-4-propyl- (CA INDEX NAME)



RN 433247-64-4 CAPLUS
 CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[(8R)-4,5,7,8-tetrahydro-8-methyl-5-oxo-4-propyl-1H-imidazo[2,1-i]purin-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




<12/04/2007>

Erich Leese

10/513699


RN 433247-69-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 4-[(8R)-4,5,7,8-tetrahydro-5-oxo-4,8-dipropyl-1H-imidazo[2,1-i]purin-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 433247-74-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-3,4,7,8-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-4-propyl-, (8S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 433247-79-1 CAPLUS
 CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[(8R)-4,5,7,8-tetrahydro-8-(1-methylethyl)-5-oxo-4-propyl-1H-imidazo[2,1-i]purin-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<12/04/2007>

Erich Leese

<12/04/2007>


Erich Leese

10/513699




RN 433247-84-8 CAPLUS
 CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-[(8S)-8-ethyl-4,5,7,8-tetrahydro-5-oxo-4-propyl-3H-imidazo[2,1-i]purin-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 433247-88-2 CAPLUS
 CN 5H-[1,3]Diazepino[2,1-i]purin-5-one, 1,4,7,8,9,10-hexahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-4-propyl- (9CI) (CA INDEX NAME)

10/513699




RN 433247-93-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-(4-hydroxybicyclo[2.2.2]oct-1-yl)-8-[(4-hydroxyphenyl)methyl]-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 433247-98-4 CAPLUS
 CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-(1,4,5,7,8,9-hexahydro-5-oxo-4-propylpyrimido[2,1-i]purin-2-yl)- (9CI) (CA INDEX NAME)



<12/04/2007>


Erich Leese

<12/04/2007>

Erich Leese


10/513699

RN 433248-03-4 CAPLUS
 CN Bicyclo[2.2.2]octane-1-carboxylic acid, 4-(4,5,7,8,9,10-hexahydro-5-oxo-4-propyl-1H-[1,3]diazepino[2,1-1]purin-2-yl)- (9CI) (CA INDEX NAME)



RN 433248-07-0 CAPLUS
 CN Pyrimido[2,1-1]purin-5(3H)-one, 4,7,8,9-tetrahydro-2-(4-hydroxycyclo[2.2.2]oct-1-yl)-9-methyl-4-propyl-, (9R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 433248-11-4 CAPLUS
 CN Pyrimido[2,1-1]purin-5(3H)-one, 9-ethyl-4,7,8,9-tetrahydro-2-(4-hydroxycyclo[2.2.2]oct-1-yl)-4-propyl-, (9R)- (CA INDEX NAME)

Absolute stereochemistry.

<12/04/2007>

Erich Leese

10/513699




RN 433248-14-7 CAPLUS
 CN SH-imidazo[2,1-1]purin-5-one, 1,4,7,8-tetrahydro-2-(4-hydroxycyclo[2.2.2]oct-1-yl)-8-(1-methylethyl)-4-propyl-, (8R)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 433246-43-6
CMF C21 H31 NS O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H31 NS O2

<12/04/2007>

Erich Leese

<12/04/2007>

Erich Leese

10/513699

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:414265 CAPLUS
 DOCUMENT NUMBER: 137:16571
 TITLE: Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor
 AUTHOR(S): Gao, Zhan-Quo; Chen, Aishe; Barak, Dov; Kim, Soo-Kyung; Muller, Christa E.; Jacobson, Kenneth A.
 CORPORATE SOURCE: Molecular Recognition Section, Laboratory of Bioorganic Chemistry, NIDDK, National Institutes of Health, Bethesda, MD, 20892, USA
 SOURCE: Journal of Biological Chemistry (2002), 277(21), 19056-19063
 CODEN: JBCHA3; ISSN: 0021-9258
 PUBLISHER: American Society for Biochemistry and Molecular Biology
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Ligand recognition has been extensively explored in G protein-coupled A1, A2A, and A2B adenosine receptors but not in the A3 receptor, which is cerebroprotective and cardioprotective. We mutated several residues of the human A3 adenosine receptor, including transmembrane domains 3 and 6 and the second extracellular loop, which have been predicted by previous modeling to be involved in the ligand recognition, including His95, Trp243, Leu244, Ser247, Asn250, and Lys152. The W250A mutant receptor lost the ability to bind both radiolabeled agonist and antagonist. The H95A mutation significantly reduced affinity of both agonist and antagonist. In contrast, the K152A (E152), W243A (6.4%), and W243F (6.4%) mutations did not significantly affect the agonist binding but decreased antagonist affinity by approx. 3-38-fold, suggesting that these residues were critical for the high affinity of A3 adenosine receptor antagonists. Activation of phospholipase C by wild type (WT) and mutant receptors was measured. The A3 agonist 2-chloro-N6-(3-iodobenzyl)-5'-N-methylcarbamoyladenosine stimulated phosphoinositide turnover in the WT but failed to evoke a response in cells expressing W243A and W243F mutant receptors, in which agonist binding was less sensitive to guanosine 5'-γ-chlorophosphate than in WT. Thus, although not important for agonist binding, Trp243 was critical for receptor activation. The results were interpreted using a rhodopsin-based model of ligand-A3 receptor interaction.
 IT 444717-56-0, PSB 11
 RL: BSB (Biological study, unclassified); BIOL (Biological study)
 (Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor)


RN 444717-56-0 CAPLUS
 CN SH-Imidazo[2,1-1]purin-5-one, 8-ethyl-3,4,7,8-tetrahydro-4-methyl-2-phenyl-, (8R)- (CA INDEX NAME)

Absolute stereochemistry.

<12/04/2007>


Erich Leese

10/513699



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 30 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:97704 CAPLUS
 DOCUMENT NUMBER: 137:78913
 TITLE: (3H)-8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-1]purin-5-one ((3H)PSB-11), a Novel High-Affinity Antagonist Radioligand for Human A3 Adenosine Receptors
 AUTHOR(S): Muller, Christa E.; Diekmann, Martina; Thorand, Mark; Osala, Vesa
 CORPORATE SOURCE: University of Bonn, Pharmaceutical Institute, Bonn, D-53115, Germany
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(3), 501-503
 CODEN: BMCLB8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OI



AB This study describes the preparation and binding properties of (3H)PSB-11 (I, R = 3H), a novel, potent, and selective antagonist radioligand for human A3 adenosine receptors (A3Rs). I (R = 3H) was prepared by hydrogenation of I (R = Cl) with tritium gas. (3H)PSB-11 binding to membranes of Chinese hamster ovary (CHO) cells expressing the human A3 AR was saturable and reversible. Saturation expts. showed that (3H)PSB-11 labeled a single class of binding sites with high affinity (KD = 4.8 nM) and limited capacity (Bmax = 3500 fmol/mg of protein). PSB-11 is a highly selective for the human A3 adenosine receptor subtypes. The new radioligand shows an extraordinarily low degree of non-specific binding rendering it a very useful tool for studying the (patho)physiol. roles of A3 ARs.
 IT 439902-54-2

<12/04/2007>


Erich Leese

RL: RCT (Reactant); RACT (Reactant or reagent)
(hydrogenation with tritium gas)

RN 439902-54-2 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-4-methyl-2-(2,3,5-trichlorophenyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 439902-55-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and binding to human A3 adenosine receptor)

RN 439902-55-3 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-4-methyl-2-(phenyl-2,3,5-tri-), (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LA ANSWER 31 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:551386 CAPLUS

Correction of: 2001:469404


DOCUMENT NUMBER: 135:92647

<12/04/2007>

Erich Leese

<12/04/2007>

Erich Leese



AB Title compds. [I]; XYZ = R1NC(O) N:CW; R1 = (CH2)2CH3, cyclopentmethyl; W = CH2CH(CO2H)CH3, V1 = H, SCH3, OCH2CH2CH2SCH3, OCH2CH2CH2SO2CH3; R2 = C(CH3)3, (CH2)2CH3; V2 = H, cyclopentyl, Br, SCH3, ClCH2, CO2CH3; R3 = H, CH2COCH3, CH2C6H5, V4 = H, C(CH3)3, CH2C6H5, CH2Cl, CH3NHC6H5, V5 = H, C(CH3)3, CH2C6H5, CH2Cl, CH3NHC6H5, CH2N2, heterocyclimethyl, CH2SO2CH3; V6 = H, CH2C6H5, 3-pyridyl; n = 1, 2; dotted line = single bond, double bond) and pharmaceutically acceptable salts are prepared as insulin secretion enhancers, blood sugar lowering agents, and remedy for diabetes complications. Thus, the title compound II was prepared and biol. tested.


IT 348167-57-7P 348169-57-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of fused purine derivs. as insulin secretion enhancers)

RN 348167-57-7 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 2-(ethoxymethyl)-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348169-57-3 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 2-(ethylthio)methyl-1,4,7,8-tetrahydro-8-

Correction of: 135:76901
Preparation of fused purine derivatives as insulin secretion enhancers
Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakanishi, Satoshi
Kyowa Hakko Kogyo Co., Ltd., Japan
PCT Int. Appl. 26 pp.
Coden: PIXXD2
Document Type: Patent
Language: Japanese
Family Acc. Num. Count: 1
Patent Information:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE				
WO 2001047931	A1	20010505	WO 2000-JP9160	20001222				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DR, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KO, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW	DE: DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BP, BJ, CF, CO, CI, CM, GA, GN, OM, ML, MR, NE, SN, TD, TO	CA 2395414	A1	20010705	CA 2000-2395414	20001222		
AU 2001022235	A5	20010709	AU 2001-22235	20001222				
EP 1251130	A1	20021023	EP 2000-985847	20001222				
EP 1251130	B1	20050216	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	AT 289311	T	20050315	AT 2000-985847	20001222
ES 2238335	T3	20050901	ES 2000-985847	20001222				
US 2003176698	A1	20030918	US 2002-149433	20021022				
US 7005430	B2	20060228	PRIORITY APPLN. INFO.: JP 1999-366313	JP 1999-366313	A 19991224			
			OTHER SOURCE(S): MARPAT 135:92647	MARPAT 135:92647	WO 2000-JP9160	W 20001222		
			GI					

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 135:92647


(phenylmethyl)-4-propyl-, (8R)-, (2S)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 348169-56-2

CMF C20 H25 N5 O 8

Absolute stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



IT 348165-49-1P 348165-93-5P 348166-04-1P

348166-05-2P 348166-06-3P 348166-07-4P

348166-22-3P 348166-23-4P 348166-24-5P

348166-27-6P 348166-28-9P 348166-30-3P

348166-31-4P 348166-40-5P 348166-91-6P

348167-33-9P 348167-35-1P 348167-44-2P

348167-46-4P 348167-47-5P 348167-50-0P

348167-51-6P 348167-58-4P 348167-60-3P

348169-45-9P 348169-76-6P 348169-80-2P

348362-72-2P 349554-64-9P 349554-69-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fused purine derivs. as insulin secretion enhancers)

RN 348165-49-1 CAPLUS


CN 5H-Imidazo[2,1-i]purin-5-one, 2-(cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-(4-pyridinylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/513699



RN 348166-93-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 348166-04-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(2-methyl-4-thiazolylmethyl)-4-propyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 348166-05-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(pyrazinylmethyl)- (9CI) (CA INDEX NAME)


<12/04/2007>

Erich Leese


10/513699




RN 348166-06-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 348166-07-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2,4-dipropyl-8-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 348166-22-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(1,1-dimethylethyl)-1,4,7,8-tetrahydro-4-propyl-8-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 348166-23-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-(1-methylcyclohexyl)-4-

<12/04/2007>

Erich Leese


10/513699

propyl-8-(4-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 348166-24-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-4-propyl-8-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 348166-27-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 4-(cyclopropylmethyl)-2-(1,1-dimethylethyl)-1,4,7,8-tetrahydro-8-(4-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 348166-28-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-4-ethyl-1,4,7,8-tetrahydro-8-(4-pyridinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)

10/513699




●2 HCl

RN 348166-30-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-1-(methoxymethyl)-8-[(methylsulfonyloxy)methyl]-4-propyl- (9CI) (CA INDEX NAME)



RN 348166-31-4 CAPLUS
 CN 1H-Isolindole-1,3(2H)-dione, 2-[(2-cyclopentyl-4,5,7,8-tetrahydro-1-(methoxymethyl)-5-oxo-4-propyl-1H-imidazo[2,1-i]purin-8-yl)methyl]- (9CI) (CA INDEX NAME)



RN 348166-40-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-(aminomethyl)-2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-, dihydrochloride (9CI) (CA INDEX NAME)


<12/04/2007>

Erich Leese

<12/04/2007>


Erich Leese

10/513699




● 2 HCl

RN 348166-91-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-(1H-pyrazol-1-ylmethyl)-, (9CI) (CA INDEX NAME)




RN 348167-33-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-(1H-pyrazol-1-ylmethyl)-, (9CI) (CA INDEX NAME)



RN 348167-35-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-(chloromethyl)-2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-, hydrochloride (9CI) (CA INDEX NAME)


10/513699



● x HCl


RN 348167-44-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-bromo-1,4,7,8-tetrahydro-1,8-bis(phenylmethyl)-4-propyl-, (8R)-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348167-46-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-1,8-bis(phenylmethyl)-4-propyl-2-(1-pyrrolidinyl)-, (8R)-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348167-49-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-(1-hydroxycyclopentyl)-8-(phenylmethyl)-4-propyl-, (8R)-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<12/04/2007>

Erich Leese

<12/04/2007>


Erich Leese

10/513699




RN 348167-50-0 CAPLUS
 CN 1H-Imidazo[2,1-i]purine-2-carboxaldehyde, 4,5,7,8-tetrahydro-5-oxo-1,8-bis(phenylmethyl)-4-propyl-, (8R)-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348167-51-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(chloromethyl)-1,4,7,8-tetrahydro-1,8-bis(phenylmethyl)-4-propyl-, (8R)-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348167-58-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(ethoxymethyl)-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 348167-57-7
 CMP C20 H25 N5 O2

10/513699


Absolute stereochemistry.



CM 2


CRN 110-17-8
 CMP C4 H4 O4

Double bond geometry as shown.



RN 348167-60-2 CAPLUS
 CN 1H-Imidazo[2,1-i]purine-2-carboxylic acid, 4,5,7,8-tetrahydro-5-oxo-1,8-bis(phenylmethyl)-4-propyl-, methyl ester, (8R)-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348169-45-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-[(phenylmethoxy)methyl]-8-(phenylmethyl)-4-propyl-, (8R)-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 348169-44-8
 CMP C25 H27 N5 O2

Absolute stereochemistry.


<12/04/2007>

Erich Leese

<12/04/2007>

Erich Leese


10/513699




CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

RN 348169-76-6 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-(2-hydroxy-2-methylpropyl)-8-(phenylmethyl)-, monohydrochloride, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 348169-80-2 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-(3-hydroxy-3-methylbutyl)-8-(phenylmethyl)-, monohydrochloride, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/513699



● HCl

RN 348369-73-2 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclobutyl-1,4,7,8-tetrahydro-4-propyl-8-(4-pyridinylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 349554-64-9 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-2-(tetrahydro-2-furanyl)-, (8R)-, (2S,3S)-2,3-dihydroxybutanediolate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 349554-63-8
CMF C21 H25 N5 O2

Absolute stereochemistry.


<12/04/2007>

Erich Leese

<12/04/2007>

Erich Leese


10/513699



CM 2

CRN 147-71-7
CMF C4 H6 O6


Absolute stereochemistry.

RN 349554-69-4 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-(4-pyridinylmethyl)-, (8R)-, (2S,3S)-2,3-dihydroxybutanediolate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 348165-49-1
CMF C21 H26 N6 O

Absolute stereochemistry.




CM 2


10/513699

CRN 147-71-7
CMF C4 H6 O6


Absolute stereochemistry.

IT 348621-36-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of fused purine derivs. as insulin secretion enhancers)
RN 348621-36-3 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-(hydroxymethyl)-1,8-bis(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 254426-65-8P 348393-40-8P 348621-37-4P
348621-39-6P 348621-41-0P 348621-42-1P
348621-43-2P 349554-72-9P 349554-74-1P
349585-63-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fused purine derivs. as insulin secretion enhancers)
RN 254426-65-8 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-1,8-bis(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese

10/513699


RN 348621-40-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-bromo-1,4,7,8-tetrahydro-1-(methoxymethyl)-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348621-37-4 CAPLUS
 CN 1H-Imidazo[2,1-i]purine-4(SH)-acetic acid, 2-cyclopentyl-7,8-dihydro-5-oxo-1,8-bis(phenylmethyl)-, methyl ester, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348621-39-6 CAPLUS
 CN 1H-Imidazo[2,1-i]purine-2-propanoic acid, 4,5,7,8-tetrahydro-5-oxo-8-(phenylmethyl)-4-propyl-, methyl ester, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348621-41-0 CAPLUS


<12/04/2007>

Erich Leese

10/513699


RN 348621-42-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-((4-fluorophenyl)methyl)-1,4,7,8-tetrahydro-1-(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348621-43-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-((4-fluorophenyl)methyl)-1,4,7,8-tetrahydro-1-(phenylmethyl)-4-(2-(tetrahydro-2H-pyran-2-yl)oxyethyl)-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/513699


RN 349554-72-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-(3-hydroxypropyl)-1,8-bis(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 349554-74-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(1,1-dimethylethyl)-1,4,7,8-tetrahydro-1,8-bis(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 349585-63-3 CAPLUS
 CN Carbamic acid, [(trans-4-((8R)-4,5,7,8-tetrahydro-5-oxo-8-(phenylmethyl)-4-propyl-1H-imidazo[2,1-i]purin-2-yl)cyclohexyl)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/513699



IT 348169-71-1P 348169-79-9P 349554-73-0P
 RL: RCT (Reactant); BPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
 USES (Uses)
 (preparation of fused purine derivs. as insulin secretion enhancers)
 RN 348169-71-1 CAPLUS
 CN 1H-Imidazo[2,1-i]purine-4(5H)-acetic acid, 2-cyclopentyl-7,8-dihydro-5-oxo-8-(phenylmethyl)-, hydrochloride, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



• x HCl

RN 348169-79-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-[2-(2-methyl-1,3-dioxolan-2-yl)ethyl]-8-(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese



RN 349554-73-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-(3-hydroxypropyl)-8-(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 348149-82-6P 348165-85-5P 348166-21-2P
 348166-25-6P 348166-29-0P 348167-31-7P
 348167-32-8P 348167-34-0P 348167-36-2P
 348167-37-3P 348167-38-4P 348167-39-5P
 348167-40-6P 348167-41-9P 348167-42-0P
 348167-43-1P 348167-45-3P 348167-47-5P
 348167-48-6P 348167-52-3P 348167-56-6P
 348167-59-9P 348167-61-3P 348167-62-4P
 348167-63-5P 348168-24-1P 348168-25-2P
 348169-42-7P 348169-47-1P 348169-48-2P
 348169-52-0P 348169-53-9P 348169-54-0P
 348169-59-5P 348169-72-2P 348169-74-4P
 348169-75-5P 348169-77-7P 348169-78-8P
 348169-81-3P 348169-82-4P 348169-84-6P
 348169-85-7P 349554-62-7P 349585-60-0P
 349585-61-1P 349585-62-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of fused purine derivs. as insulin secretion enhancers)
 RN 348149-82-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-(4-pyridinylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<12/04/2007>

Erich Leese




RN 348165-85-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-(2-pyridinylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348166-21-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclohexyl-1,4,7,8-tetrahydro-4-propyl-8-(4-pyridinylmethyl)-, (8R)- (9CI) (CA INDEX NAME)




● 2 HCl


RN 348166-29-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(1-methylsulfonyloxy)methyl]-1-(phenylmethyl)-4-propyl-, (9CI) (CA INDEX NAME)



RN 348167-31-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(1H-imidazol-1-ylmethyl)-4-propyl-, (9CI) (CA INDEX NAME)




RN 348167-32-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-(1H-1,2,4-triazol-1-ylmethyl)-, (9CI) (CA INDEX NAME)



<12/04/2007>


Erich Leese

RN 348167-34-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-(1H-benzimidazol-1-ylmethyl)-2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 348167-36-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(phenylamino)methyl]-4-propyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 348167-37-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(1-piperidinylmethyl)-4-propyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 348167-38-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-

<12/04/2007>

Erich Leese


10/513699

(1-pyrrolidinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 348167-39-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(4-morpholinylmethyl)-4-propyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 348167-40-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(4-phenylmethyl)-1-piperazinyl]methyl-4-propyl-, trihydrochloride (9CI) (CA INDEX NAME)



● 3 HCl


RN 348167-41-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(4-phenyl-1-piperazinyl)methyl]-4-propyl-, trihydrochloride (9CI) (CA INDEX NAME)

<12/04/2007>

Erich Leese


10/513699

NAME)




● 3 HCl

RN 348167-42-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(4-phenylmethyl)-1-piperidinyl]methyl-4-propyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 348167-43-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(4-phenylmethyl)amino]methyl-4-propyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 348167-45-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-1-(methoxymethyl)-2-


<12/04/2007>

Erich Leese

10/513699


(methylthio)-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348167-47-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-2-(1-pyrrolidinyl)-, monohydrochloride, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 348167-48-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-(4-morpholinyl)-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




<12/04/2007>

Erich Leese

10/513699


5H-Imidazo[2,1-i]purin-5-one, 2-[(dimethylamino)methyl]-1,4,7,8-tetrahydro-

Absolute stereochemistry.




RN 348167-56-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-2-(1-piperidinylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348167-59-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-[(4R,5R)-4,5-dimethyl-1,3-dioxolan-2-yl]-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




<12/04/2007>

Erich Leese

10/513699


RN 348167-61-3 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-(1-hydroxy-1-methylethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348167-62-4 CAPLUS
CN Piperidine, 1-[(8R)-4,5,7,8-tetrahydro-5-oxo-8-(phenylmethyl)-4-propyl-1H-imidazo[2,1-i]purin-2-yl]carbonyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348167-63-5 CAPLUS
CN Morpholine, 4-[(8R)-4,5,7,8-tetrahydro-5-oxo-8-(phenylmethyl)-4-propyl-1H-imidazo[2,1-i]purin-2-yl]carbonyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese

10/513699

RN 348169-43-7 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-(1,4-dioxaspiro[4.4]non-6-yl)-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348169-47-1 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-(methoxyphenylmethyl)-8-(phenylmethyl)-4-propyl-, (8R)-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CN 348169-46-0
CMP C25 H27 N5 O2

Absolute stereochemistry.


10/513699



CM 2


CN 110-17-8
CMP C4 H4 O4

Double bond geometry as shown.



RN 348169-48-2 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-(2-methoxyethyl)-8-(phenylmethyl)-4-propyl-, monohydrochloride, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 348169-52-8 CAPLUS
CN 1H-Imidazo[2,1-i]purine-2-propanoic acid, 4,5,7,8-tetrahydro-5-oxo-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<12/04/2007>

Erich Leese

<12/04/2007>


Erich Leese

10/513699



RN 348169-53-9 CAPLUS
 CN 1-Piperidinocarboxylic acid, 4-[(1R)-6-(1,1-dimethylethyl)-4,5,7,8-tetrahydro-5-oxo-4-propyl-1H-imidazo[2,1-i]purin-2-yl]-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348169-54-0 CAPLUS
 CN 1-Piperidinocarboxylic acid, 4-[(1R)-4,5,7,8-tetrahydro-5-oxo-8-(phenylmethyl)-4-propyl-1H-imidazo[2,1-i]purin-2-yl]-, 1,1-dimethylethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/513699




● HCl
 RN 348169-59-5 CAPLUS
 SH-Imidazo[2,1-i]purin-5-one, 2-[(ethylsulfonyl)methyl]-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 348169-58-4
 CMF C20 H25 N5 O3 S


Absolute stereochemistry.



CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.



RN 348169-72-2 CAPLUS
 CN 1H-Imidazo[2,1-i]purine-4(5H)-acetamide, 2-cyclopentyl-7,8-dihydro-5-oxo-8-

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese

10/513699

(phenylmethyl)-N-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348169-74-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-[(3-(2-oxo-3-oxazolidinyl)propyl)-8-(phenylmethyl)-, (8R)-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 348169-73-3
 CMF C25 H30 N6 O3


Absolute stereochemistry.



CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.




RN 348169-75-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(4-fluorophenyl)methyl]-1,4,7,8-tetrahydro-4-(2-hydroxyethyl)-, monohydrochloride, (8R)- (9CI)

10/513699

(CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 348169-77-7 CAPLUS
 SH-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-(3-hydroxypropyl)-8-(phenylmethyl)-, monohydrochloride, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 348169-78-8 CAPLUS
 SH-Imidazo[2,1-i]purin-5-one, 2-(1,1-dimethylethyl)-1,4,7,8-tetrahydro-4-(3-hydroxypropyl)-8-(phenylmethyl)-, monohydrochloride, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<12/04/2007>

Erich Leese

<12/04/2007>

Erich Leese


10/513699



● HCl

RN 348169-81-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5(1H)-one, 2-(1,1-dimethylethyl)-1,4,7,8-tetrahydro-4-(3-hydroxy-3-methylbutyl)-8-(phenylmethyl)-, monohydrochloride, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 348169-82-4 CAPLUS
 CN Pyrimido[2,1-i]purin-5(1H)-one, 2-(ethoxymethyl)-4,7,8,9-tetrahydro-9-(phenylmethyl)-4-propyl-, (9R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/513699



RN 348169-84-6 CAPLUS
 CN Pyrimido[2,1-i]purin-5(1H)-one, 2-(ethoxymethyl)-4,7,8,9-tetrahydro-9-(phenylmethyl)-4-propyl-, (8E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 348169-83-5
 CMF C21 H27 N5 O2



CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.



RN 348169-85-7 CAPLUS
 CN Pyrimido[2,1-i]purin-5(1H)-one, 2-cyclopentyl-4,7,8,9-tetrahydro-4-propyl-8-(3-pyridinyl)- (9CI) (CA INDEX NAME)


<12/04/2007>

Erich Leese

<12/04/2007>

Erich Leese

10/513699




RN 349585-62-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5(1H)-one, 2-cyclobutyl-1,4,7,8-tetrahydro-4-propyl-8-(4-pyridinylmethyl)-, (8R)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 348362-73-2
 CMF C20 H24 N6 O


Absolute stereochemistry.



CM 2

CRN 147-71-7
 CMF C4 H6 O6


Absolute stereochemistry.



RN 349585-60-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5(1H)-one, 1,4,7,8-tetrahydro-2-(trans-4-hydroxycyclohexyl)-8-(phenylmethyl)-4-propyl-, monohydrochloride, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/513699



● HCl

RN 349585-61-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5(1H)-one, 2-(trans-4-(aminomethyl)cyclohexyl)-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 349585-62-2 CAPLUS
 CN Acetamide, N-[(trans-4-[(8R)-4,5,7,8-tetrahydro-5-oxo-8-(phenylmethyl)-4-propyl-1H-imidazo[2,1-i]purin-2-yl]cyclohexyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

<12/04/2007>

Erich Leese

<12/04/2007>

Erich Leese



• HCl

L4 ANSWER 32 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:100157 CAPLUS

DOCUMENT NUMBER: 134:275332

TITLE: Phosphodiesterase 4 isoenzyme inhibitory activity of 3-phenylxanthines and 4-phenyl[1]condensed-purines

AUTHOR(S): Suzuki, Hirokazu; Sawanishi, Hiroyuki; Yamamoto, Ken-ichi

CORPORATE SOURCE: Department of Synthetic Chemistry, Faculty of Pharmaceutical Science, Hokuriku University, Kanazawa, 920-1181, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (2001), 49(2), 188-191

PUBLISHER: CPBTAL, ISSN: 0009-2363

DOCUMENT TYPE: Journal

LANGUAGE: English


AB On the basis of our study on the structure-activity relationships of 1,3,7-alkylxanthines and condensed-purines on cAMP: cGMP phosphodiesterase 4 (PDE 4) isoenzyme inhibition, we investigated the synthesis and the inhibitory activity of 3-phenylxanthines and 4-phenyl[1]condensed-purine derivatives. Xanthines and condensed-purines with the Ph group exhibited potent and selective PDE 4 inhibitory activity.

IT 195869-73-9

RL BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (phosphodiesterase 4 isoenzyme inhibitory activity of 3-phenylxanthines and 4-phenyl[1]condensed-purines)

RN 195869-73-9 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-3,4-dipropyl- (9CI) (CA INDEX NAME)




IT 333447-87-3P 333447-88-4P 333447-89-5P

RL BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (phosphodiesterase 4 isoenzyme inhibitory activity of 3-phenylxanthines and 4-phenyl[1]condensed-purines)


RN 333447-87-3 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-4-phenyl-1-propyl- (9CI) (CA INDEX NAME)



RN 333447-88-4 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-4-phenyl- (9CI) (CA INDEX NAME)



RN 333447-89-5 CAPLUS


CN Pyrimido[2,1-i]purin-5(1H)-one, 4,7,8,9-tetrahydro-4-phenyl- (9CI) (CA INDEX NAME)

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese



RN 333447-90-8 CAPLUS

CN Pyrimido[2,1-i]purin-5(1H)-one, 4,7,8,9-tetrahydro-4-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 33 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:6279 CAPLUS

DOCUMENT NUMBER: 134:216806

TITLE: 3-Aryl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: A New Class of Selective A1 Adenosine Receptor Antagonists

AUTHOR(S): De Bettimo, Federico; Primofiore, Giampaolo; Taliani, Sabrina; Marini, Anna Maria; La Motta, Concettina; Novellino, Ettore; Greco, Giovanni; Lavecchia, Antonio; Trincavelli, Letizia; Martini, Claudia

CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Universita di Pisa, Pisa, 56126, Italy

SOURCE: Journal of Medicinal Chemistry (2001), 44(3), 316-327


PUBLISHER: JMCMAR, ISSN: 0022-2623

DOCUMENT TYPE: American Chemical Society

LANGUAGE: Journal

OTHER SOURCE(S): English

G1 CASREACT 134:216806



AB Radioligand binding assays using bovine cortical membrane preps. and biochem. in vitro studies revealed that various 3-aryl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one (ATB1) derivs., previously reported by the authors as ligands of the central benzodiazepine receptor (BzR) (Primofiore, G. et al. J. Med. Chemical 2000, 43, 96-102), behaved as antagonists at the A1 adenosine receptor (A1AR). Alkylation of the nitrogen at position 10 of the triazinobenzimidazol nucleol confers selectivity for the A1AR vs. the BzR. The proposed 10-alkyl analogs of the ATB1 (10-methyl-3-phenyl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one (I)) displayed a Ki value of 6.3 nM at the A1AR without binding appreciably to the adenosine A2A and A3 nor to the benzodiazepine receptor. Pharmacophore-based modeling studies in which I was compared against a set of well-established A1AR antagonists suggested that three hydrogen bonding sites (H81 acceptor, H82 and H83 donor) and three lipophilic pockets (L1, L2, and L3) might be available to antagonists within the A1AR binding cleft. According to the proposed pharmacophore scheme, the lead compound I engages interactions with the H82 site (via the N2 nitrogen) as well as with the L2 and L3 sites (through the pendant and the fused benzene rings). The results of these studies prompted the replacement of the Me with more lipophilic groups at the 10-position (to fill the putative L1 lipophilic pocket) as a strategy to improve A1AR affinity. Among the new compds. synthesized and tested, the 3,10-diphenyl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one (II) was characterized by a Ki value of 16 nM which represents a 5-fold gain of affinity. A new lead compound was built to highlight the binding mode of II and two well-known A1AR antagonists and to guide future lead optimization projects. In the authors docking simulations, II receives a hydrogen bond (via the N1 nitrogen) from the side chain of Asn247 (corresponding to the H81 and H82 sites) and fills the L1, L2, and L3 lipophilic pockets with the 10-Ph, 3-Ph, and fused benzene rings, resp.

IT 143394-66-7

RL BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (3-aryl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones as new class of selective A1 adenosine receptor antagonists)

RN 143394-66-7 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-2-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1,4,7,8-tetrahydro-4-propyl- (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

<12/04/2007>

Erich Leese

<12/04/2007>

Erich Leese



REFERENCE COUNT: 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

14 ANSWER 34 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000-34744 CAPLUS

DOCUMENT NUMBER: 132-81800 Condensed purine derivatives as remedies for diabetes

TITLE: Shinoda, Junichi; Ohta, Yoshihisa; Takasaki, Kotaro; Suda, Miko; Kuwata, Hideaki; Yano, Hiroshi; Nakaniishi, Satoshi; Matsuda, Yuzuru

INVENTOR(S): Kyowa Hakko Kogyo Co., Ltd., Japan

SOURCE: PCT Int. Appl., 98 pp.

CODEN: PIIXD2

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000001388	A1	20000113	WO 1999-JP3583	19990702
W: AU, BG, BR, CA, CN, CZ, HU, ID, IL, IN, JP, KR, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, BE				
CA 2336412	A1	20000113	CA 1999-3336412	19990702
AU 9943968	A	20000124	AU 1999-43968	19990702
EP 1092435	A1	20010418	EP 1999-326903	19990702
EP 1092435	B1	20070404		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
AT 358484	T	20070415	AT 1999-326903	19990702
US 6489331	B1	20021203	US 2001-719570	20010409
PRIORITY APPLN. INFO.:			JP 1998-187705	A 19980702
			WO 1999-JP3583	W 19990702

01



AB Remedies for diabetes which contain condensed purine derivs. as the active ingredient compds. represented by general formula (I) or physiol. acceptable salts thereof wherein R1 represents hydrogen, lower alkyl, optionally substituted aryl or optionally substituted heteroaryl; R2 represents hydrogen, lower alkyl, optionally substituted aryl, optionally substituted aryl or optionally substituted heteroaryl; R3 represents hydrogen, lower alkyl or optionally substituted aryl; X1 and X2 independently represent each hydrogen, lower alkyl, optionally substituted aryl or optionally substituted aryl; and n is an integer from 0 to 3. I can promote insulin secretion. Formulation examples of I were given.

143394-68-7P 143394-10-2P 254426-34-1P

254426-35-2P 254426-36-3P 254426-37-4P

254426-38-5P 254426-39-6P 254426-40-9P

254426-41-0P 254426-42-1P 254426-43-2P

254426-44-3P 254426-45-4P 254426-46-5P

254426-47-6P 254426-48-7P 254426-49-8P

254426-50-1P 254426-51-2P 254426-52-3P

254426-53-4P 254426-54-5P 254426-55-6P

254426-56-7P 254426-57-8P 254426-58-9P

254426-59-0P 254426-60-1P 254426-61-4P

254426-62-5P 254426-63-6P 254426-64-7P

254426-65-8P 254426-66-9P 254426-67-0P

254426-68-1P 254426-69-2P 254426-70-5P

254426-71-6P 254426-72-7P 254426-73-8P

254426-74-9P 254426-75-0P 254426-76-1P

254426-78-2P 254426-79-3P 254426-80-4P

254426-80-7P 254426-81-8P 254426-82-9P

254426-83-0P 254426-84-1P 254426-85-2P

254426-86-3P 254426-87-4P 254426-88-5P

254426-89-6P 254426-90-9P 254426-91-0P

254426-92-1P 254426-93-2P 254426-94-3P

254426-95-4P 254426-96-5P 254426-97-6P

254426-98-7P 254426-99-8P 254427-00-4P

254427-01-5P 254427-02-6P 254427-03-7P

254427-04-8P 254427-05-9P 254427-06-0P

254427-07-1P 254427-08-2P 254427-09-3P

254427-10-6P 254427-11-7P 254427-12-8P

254427-13-9P 254427-14-0P 254427-15-1P

254427-16-2P 254427-17-3P 254427-18-4P

254427-19-5P 254427-20-6P 254427-21-9P

254427-22-0P 254427-23-1P 254427-24-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(condensed purine derivs. as remedies for diabetes)

RN 143394-68-7 CAPLUS

<12/04/2007>


Erich Leese

<12/04/2007>

Erich Leese

CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-2-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1,4,7,8-tetrahydro-4-propyl-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 143394-70-1 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-2-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1,4,7,8-tetrahydro-4-propyl-, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 254426-34-1 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 2-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1,4,7,8-tetrahydro-8-(1-methylethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 254426-35-2 CAPLUS


CN 5H-Imidazo[2,1-i]purin-5-one, 2-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1,4,7,8-tetrahydro-8-(1-methylethyl)-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254426-36-3 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 2-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1,4,7,8-tetrahydro-4-propyl-, (9CI) (CA INDEX NAME)



RN 254426-37-4 CAPLUS

CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-methyl-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

<12/04/2007>


Erich Leese

<12/04/2007>

Erich Leese


10/513699

Absolute stereochemistry.




RN 254426-38-5 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-ethyl-1,4,7,8-tetrahydro-4-propyl-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254426-39-6 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-ethyl-1,4,7,8-tetrahydro-4-propyl-, (SS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 254426-40-9 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(1-methylethyl)-4-propyl-, (SR)- (9CI) (CA INDEX NAME)

<12/04/2007>

Erich Leese


10/513699

Absolute stereochemistry.




RN 254426-41-0 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(1-methylethyl)-4-propyl-, (SS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254426-42-1 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(2-methylpropyl)-4-propyl-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254426-43-2 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-(1,1-dimethylethyl)-1,4,7,8-


<12/04/2007>

Erich Leese


10/513699

tetrahydro-4-propyl-, (SS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 254426-44-3 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-butyl-2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-, (SS)- (9CI) (CA INDEX NAME)



RN 254426-45-4 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-(cyclohexylmethyl)-2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-, (SS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 254426-46-5 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-phenyl-4-propyl-, (SS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

<12/04/2007>


Erich Leese

10/513699




RN 254426-47-6 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (SR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254426-48-7 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (SS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 254426-49-8 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-((4-fluorophenyl)methyl)-1,4,7,8-tetrahydro-4-propyl-, (SS)- (9CI) (CA INDEX NAME)


<12/04/2007>

Erich Leese


10/513699




RN 254426-50-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(3-fluorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)



RN 254426-51-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(4-chlorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)



RN 254426-52-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(3-chlorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




RN 254426-53-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(2,6-dichlorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)


<12/04/2007>

Erich Leese


10/513699




RN 254426-54-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(4-bromophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)



RN 254426-55-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(3-bromophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




RN 254426-56-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(4-methoxyphenyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




RN 254426-57-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(4-nitrophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)

10/513699




RN 254426-58-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(4-phenylmethoxy)phenylmethyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254426-59-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(4-phenylmethoxy)phenylmethyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 254426-60-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(4-phenylmethoxy)phenylmethyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/513699



RN 254426-61-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(2-phenylmethyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)



RN 254426-62-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(2-phenylethyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)



RN 254426-63-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(2-phenylethyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<12/04/2007>

Erich Leese

<12/04/2007>


Erich Leese

10/513699




RN 254426-64-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254426-65-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-bis(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 254426-66-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-2,4-dipropyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

<12/04/2007>


Erich Leese

10/513699




RN 254426-67-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopropyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254426-68-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclobutyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254426-69-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclohexyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

<12/04/2007>

Erich Leese


Erich Leese

10/513699




RN 254426-70-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, 2-tricyclo[3.3.1.13.7]dec-1-yl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254426-71-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(cyclopentylmethyl)-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 254426-72-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-(1-methylethyl)-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/513699




RN 254426-73-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(3-furanyl)-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254426-74-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(1,1-dimethylethyl)-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254426-75-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-2-(3-thienyl)-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

<12/04/2007>


Erich Leese

<12/04/2007>


Erich Leese




RN 254426-76-1 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(4-bromophenyl)methyl]-2-cyclohexyl-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




RN 254426-77-2 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(4-chlorophenyl)methyl]-1,4,7,8-tetrahydro-2,4-dipropyl- (9CI) (CA INDEX NAME)




RN 254426-78-3 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(4-chlorophenyl)methyl]-2-cyclohexyl-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




RN 254426-79-4 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(4-chlorophenyl)methyl]-2-cyclobutyl-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)



RN 254426-80-7 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(4-fluorophenyl)methyl]-1,4,7,8-tetrahydro-2,4-dipropyl- (9CI) (CA INDEX NAME)



RN 254426-81-8 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclohexyl-8-[(4-fluorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)



<12/04/2007>


Erich Leese

<12/04/2007>


Erich Leese

RN 254426-82-9 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclobutyl-8-[(4-fluorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 254426-83-0 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-butyl-8-[(4-fluorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




RN 254426-84-1 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(4-fluorophenyl)methyl]-2-(2-furanyl)-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




RN 254426-85-2 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(4-fluorophenyl)methyl]-2-(3-furanyl)-1,4,7,8-tetrahydro-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 254426-86-3 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-(1,1-dimethylethyl)-8-[(4-fluorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254426-87-4 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(3-fluorophenyl)methyl]-1,4,7,8-tetrahydro-2,4-dipropyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254426-88-5 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclobutyl-8-[(3-fluorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese


10/513699



RN 254426-89-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(3-fluorophenyl)methyl]-1,4,7,8-tetrahydro-2-(2-methylpropyl)-4-propyl- (9CI) (CA INDEX NAME)




RN 254426-90-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-8-[(3-fluorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




RN 254426-91-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(2-fluorophenyl)methyl]-1,4,7,8-tetrahydro-2-(2-methylpropyl)-4-propyl- (9CI) (CA INDEX NAME)


10/513699




RN 254426-92-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(3-methylphenyl)methyl]-4-propyl- (9CI) (CA INDEX NAME)



RN 254426-93-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(3-iodophenyl)methyl]-4-propyl- (9CI) (CA INDEX NAME)



RN 254426-94-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(2,3-difluorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)



RN 254426-95-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(2,5-difluorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)


<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese

10/513699




RN 254426-96-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(2,5-dichlorophenyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)



RN 254426-97-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-(1,1-dimethylethyl)-1,4,7,8-tetrahydro-4-propyl-2-tricyclo[3.3.1.13.7]dec-1-yl-, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 254426-98-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-(1,1-dimethylethyl)-2-(3-furanyl)-1,4,7,8-tetrahydro-4-propyl-, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/513699




RN 254426-99-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-(1,1-dimethylethyl)-2-(3,5-dimethyl-4-isoxazolyl)-1,4,7,8-tetrahydro-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254427-00-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2,6-bis(1-methylethyl)-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254427-01-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 3-[(2-cyclopentyl-4,5,7,8-tetrahydro-5-oxo-4-propyl-1H-imidazo[2,1-i]purin-8-yl)methyl]- (9CI) (CA INDEX NAME)


<12/04/2007>

Erich Leese

<12/04/2007>


Erich Leese

10/513699




RN 254427-02-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-4-ethyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254427-03-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-4-(cyclopropylmethyl)-1,4,7,8-tetrahydro-8-(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254427-04-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(cyclopropylmethyl)-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese


10/513699



RN 254427-05-9 CAPLUS
 CN Benzoic acid, 3-[(2-cyclopentyl)-4,5,7,8-tetrahydro-5-oxo-4-propyl-1H-imidazo[2,1-i]purin-8-yl)methyl]-, (8R)- (9CI) (CA INDEX NAME)




RN 254427-06-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(1-methyl-1-phenylethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)



RN 254427-07-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(4-hydroxyphenyl)methyl]-4-propyl-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/513699




RN 254427-08-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-2-(3-pyridinyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254427-09-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-phenyl-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254427-10-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-2-(2,2,3,3-tetramethylcyclopropyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese


10/513699



RN 254427-05-9 CAPLUS
 CN Benzoic acid, 3-[(2-cyclopentyl)-4,5,7,8-tetrahydro-5-oxo-4-propyl-1H-imidazo[2,1-i]purin-8-yl)methyl]-, (8R)- (9CI) (CA INDEX NAME)




RN 254427-06-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(1-methyl-1-phenylethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)



RN 254427-07-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(4-hydroxyphenyl)methyl]-4-propyl-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/513699




RN 254427-11-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(1,3-benzodioxol-5-yl)-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254427-12-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-2-(4-pyridinyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254427-13-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese

10/513699


2-pyrazinyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 254427-14-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-2-(2-thienyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 254427-15-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-methyl-8-(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese

10/513699



RN 254427-20-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(2-(trifluoromethyl)phenyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 35 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999-9714 CAPLUS
 DOCUMENT NUMBER: 130:71627
 TITLE: Compositions and methods for preventing restenosis following revascularization procedures
 INVENTOR(S): Martin, Pauline L.; McFee, Donald A.
 PATENT ASSIGNEE(S): Discovery Therapeutics, Inc., USA
 SOURCE: PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY 'ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9857651	A1	19981223	WO 1998-US12717	19980618
W: AU, CA, JP, US				
RM: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2295195	A1	19981223	CA 1998-2295195	19980618
AU 9880740	A	19990104	AU 1998-80740	19980618
AU 740770	B2	20011115		
EP 1014995	A1	20000705	EP 1998-929099	19980618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, SE, FI				
JP 2002505687	T	20020219	JP 1999-506810	19980618
US 6372723	B1	20020416	US 1999-456432	19991208

RN 254427-21-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-[(3-phenoxyphenyl)methyl]-4-propyl- (9CI) (CA INDEX NAME)



RN 254427-22-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-[(3-(trifluoromethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 254427-23-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(3,5-bis(trifluoromethyl)phenyl)methyl]-2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese


10/513699

RN 254427-16-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-phenyl-8-(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 254427-17-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-[(4-(1,1-dimethylethyl)phenyl)methyl]-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)



RN 254427-18-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-[(1,1'-biphenyl)-2-ylmethyl]-2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




RN 254427-19-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl-8-[(3-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)

10/513699

US 2001009907 A1 20010726 US 2001-783032 20010215
 US 6339072 B2 20020115 P 19970618
 PRIORITY APPLN. INFO.: US 1997-50031P W 19980618
 WO 1998-US12717 W 19980618
 US 1999-456432 A3 19991208

AB In the present invention, a method is provided which reduces or prevents restenosis following revascularization procedures. It has now been found that selective stimulation of adenosine A2A receptors can reduce or prevent such restenosis. This method may be achieved either by: (a) the administration of selective adenosine A2A receptor agonists, (b) the administration of a selective adenosine A1 antagonist in combination with either a selective adenosine A2A receptor agonist or a non-selective adenosine agonist, or (c) the administration of a selective adenosine A1 antagonist in order to block adenosine A1 receptor activation by endogenously-released adenosine. The present invention is also directed to an improved surgical procedure that relies upon selective stimulation of adenosine A2A receptors. The degree of arterial stenosis in rabbits after angioplasty treated with the adenosine A2A selective agonist 2-cyclohexylmethylenehydrazinoadenosine was significantly less than arterial stenosis in rabbits treated with vehicle.

IT 210284-53-8
 RL: This (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compns. for preventing restenosis following revascularization
 procedures).
 RN 210284-53-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-2-(octahydro-1,5-methanopentalen-4-yl)-4-propyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITED REFERENCES ARE AVAILABLE IN THE RE FORMAT

L4 ANSWER 36 OF 46 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 1998:189162 CAPLUS
 DOCUMENT NUMBER: 129:104221
 TITLE: Purines and their pharmaceutical compositions
 INVENTOR(S): Miyamoto, Kenichi; Kasugai, Shohel; Waki, Yoshihiro; Sawanishi, Keiji
 PATENT ASSIGNEE(S): Mediscience Planning K. K., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 20 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO. KIND DATE APPLICATION NO. DATE

<12/04/2007>

Erich Leese

10/513699


 JP 10159267 A 19980616 JP 1996-319478 19961129
 PRIORITY APPLN. INFO.: OTHER SOURCE(S): MARPAT 129:104221
 GI




AB Purines I or II [R1-R3 = H, lower alkyl, (acyl-substituted) C1-6 alkyl, n = 2-4; X = CH2CH2N=N] or their pharmaco-acceptable salts are useful for pharmaceutical compns. such as bronchodilators and therapeutic agents for bone diseases. 3,6-Dipropyl-4,5-dihydro-3H-imidazo[1,2-i]purin-5-one (preparation given) inhibited phosphodiesterase-type IV with IC50 of 15 μ M.

IT 135839-22-49 195869-88-6P 195870-01-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); BPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of purines for bronchodilators and therapeutic agents for bone diseases)

RN 135839-22-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)



RN 195869-88-6 CAPLUS
 CN Pyrimido[2,1-i]purin-5(1H)-one, 4,7,8,9-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




<12/04/2007>


Erich Leese

10/513699


RN 195870-01-0 CAPLUS
 CN 5H-(1,3)Diazepino[2,1-i]purin-5-one, 1,4,7,8,9,10-hexahydro-4-propyl- (9CI) (CA INDEX NAME)



IT 195869-60-4P 195869-73-9P 195869-81-9P
 195869-95-5P 195870-05-4P 209965-37-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of purines for bronchodilators and therapeutic agents for bone diseases)
 RN 195869-60-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-1,4-dipropyl- (9CI) (CA INDEX NAME)




RN 195869-73-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-3,4-dipropyl- (9CI) (CA INDEX NAME)




RN 195869-81-9 CAPLUS
 CN Pyrimido[2,1-i]purin-5(1H)-one, 4,7,8,9-tetrahydro-1,4-dipropyl- (9CI) (CA INDEX NAME)


10/513699




RN 195869-95-5 CAPLUS
 CN Pyrimido[2,1-i]purin-5(3H)-one, 4,7,8,9-tetrahydro-3,4-dipropyl- (9CI) (CA INDEX NAME)



RN 195870-05-0 CAPLUS
 CN 5H-(1,3)Diazepino[2,1-i]purin-5-one, 3,4,7,8,9,10-hexahydro-3,4-dipropyl- (9CI) (CA INDEX NAME)



RN 209965-37-7 CAPLUS
 CN 5H-(1,3)Diazepino[2,1-i]purin-5-one, 1,4,7,8,9,10-hexahydro-1,4-dipropyl- (9CI) (CA INDEX NAME)



<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese

LA ANSWER 37 OF 46 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 1998-239226 CAPLUS
 DOCUMENT NUMBER: 128-294787
 TITLE: Preparation of fused purine derivatives as adenosine A3 receptor antagonists
 INVENTOR(S): Tsunuki, Hiroshi; Saki, Mayumi; Nonaka, Hiromi; Ichimura, Michio; Shimada, Junichi; Suzuki, Fumio; Ichikawa, Shunji; Kosaka, Nobuo
 PATENT ASSIGNEE(S): Kyowa Hekkko Kogyo Co., Ltd., Japan
 SOURCE: PCT Int. Appl. 55 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
 WO 9815955 A1 19980416 NO 1997-JP3586 19971007
 W: AU, BO, BR, CA, CN, CZ, HU, JP, KR, MX, NO, NZ, PL, RO, SG, SI, SK, UA, US, VN, AM, AZ, BY, KZ, MD, RU, TJ, TM
 R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 CA 2239881 A1 19980416 CA 1997-2239881 19971007
 AU 9744712 A 19980505 AU 1997-44712 19971007
 EP 884318 A1 19981216 EP 1997-943146 19971007
 R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
 US 6306847 B1 20011023 US 1998-90936 19980605
 PRIORITY APPLN. INFO.: JP 1996-265818 A 19961007
 WO 1997-JP3586 W 19971007

OTHER SOURCE(S): MARPAT 128:294787
 GI



AB The title compds. (I; R1 = optionally substituted aryl or aromatic heterocyclic group; R2 = H, lower alkyl, alicyclic alkyl, optionally substituted aralkyl, aryl, or an aromatic heterocyclic group; R3 = H, lower alkyl or optionally substituted aralkyl; X1, X2 = H, lower alkyl, optionally substituted aralkyl, or aryl; n = 0-3) are prepared I show an adenosine A3 receptor antagonism and have antiasthmatic, bronchodilating and itch-relieving effects. Thus 8-(p-bromophenyl)-3-ethyl-6-methylthio-3-dihydro-2H-purin-2-one (preparation given) was reacted with ethanamine and then treated with BOC2 to give 87% I (R1 = p-bromophenyl, R2 = Et, R3 = X1 = X2 = H, n = 0), which at 10-8 M showed 88% inhibitory activity against adenosine A3 receptor. A formulation containing I are also prepared
 IT 206129-80-8P 206129-82-OP 206129-84-2P
 206129-86-4P 206129-88-6P 206129-89-7P

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese

RN 206129-86-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-4,8-diethyl-1,4,7,8-tetrahydro- (9CI) (CA INDEX NAME)

RN 206129-88-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-3,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)

RN 206129-89-7 CAPLUS
 CN Pyrimido[2,1-i]purin-5(1H)-one, 2-(4-bromophenyl)-4,7,8,9-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




<12/04/2007>

Erich Leese

<12/04/2007>


Erich Leese

206129-91-1P 206129-93-3P 206129-95-5P
 206129-97-7P 206129-99-9P 206130-01-0P
 206130-03-2P 206130-05-4P 206130-07-6P
 206130-09-8P 206130-11-2P 206130-13-4P
 206130-15-6P 206130-17-8P 206130-19-0P
 206130-21-4P 206130-23-6P 206130-25-8P
 206130-26-9P 206130-27-0P 206130-28-1P
 206130-29-2P 206130-30-5P 206130-31-6P
 206130-32-7P 206130-33-8P 206130-34-9P
 206130-35-0P 206130-36-1P 206130-37-2P
 RL: BAC (Biological activity or effector, except adverse), BSU (Biological study, unclassified), BPP (Synthetic preparation), THU (Therapeutic use), BIOL (Biological study), PREP (Preparation), USES (Uses)
 (preparation of fused purine derivs. as adenosine A3 receptor antagonists)
 RN 206129-80-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-4-ethyl-1,4,7,8-tetrahydro- (9CI) (CA INDEX NAME)




● HCl

RN 206129-82-0 CAPLUS
 CN Pyrimido[2,1-i]purin-5(1H)-one, 2-(4-bromophenyl)-4-ethyl-1,4,7,8-tetrahydro- (9CI) (CA INDEX NAME)




RN 206129-84-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-4-ethyl-1,4,7,8-tetrahydro-8-methyl- (9CI) (CA INDEX NAME)


RN 206129-91-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-1,4,7,8-tetrahydro-8-methyl-4-propyl- (9CI) (CA INDEX NAME)



RN 206129-93-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-8-ethyl-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)



RN 206129-95-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(2-bromophenyl)-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)



RN 206129-97-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-2-(4-methylphenyl)-4-propyl- (9CI) (CA INDEX NAME)


<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese


10/513699



RN 206129-99-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(2-bromophenyl)-8-ethyl-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




RN 206130-01-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-2-(4-methylphenyl)-4-propyl- (9CI) (CA INDEX NAME)



RN 206130-01-2 CAPLUS
 CN 2-Propenoic acid, 3-[4-(4-ethyl-4,5,7,8-tetrahydro-5-oxo-1H-imidazo[2,1-i]purin-2-ylphenyl)-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

10/513699




RN 206130-05-4 CAPLUS
 CN 2-Propenoic acid, 3-[4-(4-ethyl-1,4,5,7,8,9-hexahydro-5-oxopyrimido[2,1-i]purin-2-yl)phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 206130-07-6 CAPLUS
 CN 2-Propenoic acid, 3-[4-(4-ethyl-1,4,5,7,8,9-hexahydro-5-oxopyrimido[2,1-i]purin-2-yl)phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 206130-09-8 CAPLUS
 CN 2-Propenoic acid, 3-[4-(4,8-diethyl-4,5,7,8-tetrahydro-5-oxo-1H-imidazo[2,1-i]purin-2-ylphenyl)-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

<12/04/2007>


Erich Leese

<12/04/2007>

Erich Leese


10/513699

Double bond geometry as shown.



RN 206130-11-2 CAPLUS
 CN 2-Propenoic acid, 3-[4-(4,8-diethyl-4,5,7,8-tetrahydro-5-oxo-1H-imidazo[2,1-i]purin-2-yl)phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 206130-13-4 CAPLUS
 CN 2-Propenoic acid, 3-[4-(4,5,7,8-tetrahydro-5-oxo-4-propyl-1H-imidazo[2,1-i]purin-2-ylphenyl)-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

10/513699



RN 206130-15-6 CAPLUS
 CN 2-Propenoic acid, 3-[4-(4,5,7,8-tetrahydro-5-oxo-4-propyl-1H-imidazo[2,1-i]purin-2-yl)phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 206130-17-8 CAPLUS
 CN 2-Propenoic acid, 3-[4-(8-ethyl-4,5,7,8-tetrahydro-5-oxo-4-propyl-1H-imidazo[2,1-i]purin-2-yl)phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


<12/04/2007>

Erich Leese

<12/04/2007>


Erich Leese

10/513699




RN 206130-19-0 CAPLUS
 CN 2-Propenoic acid, 3-[(4-(8-ethyl-4,5,7,8-tetrahydro-5-oxo-4-propyl-1H-imidazo[2,1-i]purin-2-yl)phenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 206130-21-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(3-bromophenyl)-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




RN 206130-23-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(3-bromophenyl)-8-ethyl-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)


10/513699



RN 206130-25-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-2-phenyl-4-propyl- (9CI) (CA INDEX NAME)



RN 206130-26-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-8-ethyl-1,4,7,8-tetrahydro-4-methyl- (9CI) (CA INDEX NAME)



RN 206130-27-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-8-ethyl-1,4,7,8-tetrahydro-4-phenyl- (9CI) (CA INDEX NAME)

<12/04/2007>


Erich Leese

<12/04/2007>

Erich Leese


10/513699

10/513699




RN 206130-28-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-1,4,7,8-tetrahydro-4-[(3-iodophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206130-29-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-8-ethyl-1,4,7,8-tetrahydro-4-[(3-iodophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206130-30-5 CAPLUS
 CN Pyrimido[2,1-i]purin-5(1H)-one, 2-(4-bromophenyl)-4,7,8-tetrahydro-4-[(3-iodophenyl)methyl]- (9CI) (CA INDEX NAME)

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese

10/513699


phenyl-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 206130-34-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-1,4,7,8-tetrahydro-8-phenyl-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206130-35-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-1,4,7,8-tetrahydro-8-ethyl-4-propyl-, (9CI) (CA INDEX NAME)




RN 206130-36-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(2-furanyl)-1,4,7,8-tetrahydro-4-propyl-

<12/04/2007>


Erich Leese

10/513699


(9CI) (CA INDEX NAME)



RN 206130-37-2 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-ethyl-2-(2-furanyl)-1,4,7,8-tetrahydro-4-propyl-, (9CI) (CA INDEX NAME)



IT 206130-58-7P 206130-59-8P 206130-61-2P
 206130-62-3P 206130-63-4P 206130-65-6P
 RL: RCT (Reactant); SPA (Synthetic preparation); PRBP (Préparation); RACT (Reactant or reagent)
 (preparation of fused purine derivs. as adenosine A3 receptor antagonists)
 RN 206130-58-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-4-ethyl-1,4,7,8-tetrahydro-1-[(2-trimethylsilyl)ethoxy]methyl-, (9CI) (CA INDEX NAME)



RN 206130-59-8 CAPLUS
 CN 2-Propenoic acid, 3-[(4-ethyl-4,5,7,8-tetrahydro-5-oxo-1-[(2-trimethylsilyl)ethoxy]methyl)-1H-imidazo[2,1-i]purin-2-yl]phenyl-, ethyl ester (9CI) (CA INDEX NAME)

<12/04/2007>


Erich Leese

<12/04/2007>


Erich Leese

10/513699


10/513699



RN 206130-65-6 CAPLUS
 CN 2-Propenoic acid, 3-[(4-ethyl-4,5,7,8-tetrahydro-5-oxo-1-[(2-trimethylsilyl)ethoxy]methyl)-1H-imidazo[2,1-i]purin-2-yl]phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 206130-66-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-1,4,7,8-tetrahydro-4-propyl-1-[(2-trimethylsilyl)ethoxy]methyl-, (9CI) (CA INDEX NAME)



RN 206130-68-9 CAPLUS
 CN 2-Propenoic acid, 3-[(4-ethyl-4,5,7,8-tetrahydro-5-oxo-4-propyl-1-[(2-trimethylsilyl)ethoxy]methyl)-1H-imidazo[2,1-i]purin-2-yl]phenyl-, ethyl ester (9CI) (CA INDEX NAME)

RN 206130-62-3 CAPLUS
 CN 2-Propenoic acid, 3-[(4-ethyl-4,5,7,8-tetrahydro-5-oxo-1-[(2-trimethylsilyl)ethoxy]methyl)-1H-imidazo[2,1-i]purin-2-yl]phenyl-, ethyl ester (9CI) (CA INDEX NAME)

RN 206130-63-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-4,8-diethyl-1,4,7,8-tetrahydro-1-[(2-trimethylsilyl)ethoxy]methyl-, (9CI) (CA INDEX NAME)


RN 206130-63-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-4,8-diethyl-1,4,7,8-tetrahydro-1-[(2-trimethylsilyl)ethoxy]methyl-, (9CI) (CA INDEX NAME)

<12/04/2007>

Erich Leese

<12/04/2007>

Erich Leese



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 38 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1997:603433 CAPLUS
 DOCUMENT NUMBER: 127:24112
 TITLE: Selective Inhibitors of Cyclic AMP-Specific Phosphodiesterases: Heterocycle-Condensed Purines
 AUTHOR(S): Savanishi, Hiroyuki; Suzuki, Hirokazu; Yamamoto, Shinji; Maki, Yoshihiro; Kasugai, Shiohei; Ohya, Keiichi; Suzuki, Nagao; Miyamoto, Ken-ichi; Takagi, Kenzo
 CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, 920-11, Japan
 SOURCE: Journal of Medicinal Chemistry (1997), 40(20), 3248-3253
 PUBLISHER: JCMCRA, ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB To reverse the adverse reactions of alkylxanthines and to develop novel inhibitors of cAMP-specific phosphodiesterase (PDE IV), a series of heterocycle-condensed purines were designed and synthesized. Some of these new compds. had similar or more potent and selective inhibitory activity against PDE IV than known PDE IV inhibitors. The tracheal-relaxant activity of these compds. was closely correlated with their PDE IV inhibitory activity. Moreover, these new analogs did not have any pos.-cholinotropic action or adenosine-antagonistic action on isolated heart preps., which are the particular adverse reactions of alkylxanthines. Among them, 3,4-dipropyl-4,5,7,8-tetrahydro-3H-imidazo[2,1-i]purin-5-one, which was the most selective and potent PDE IV inhibitor, did not cause emesis in *Suncus murinus* at a dosage range of 10-100 mg/kg (p.o.), while its imidazole analog and known PDE IV inhibitor such as rolipram and denbufylline caused emesis even at 10 or 30 mg/kg.
 IT 135839-22-4P 195869-98-6P 195870-01-0P
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (preparation and structure of heterocycle-condensed purines as selective inhibitors of cAMP-specific phosphodiesterase)
 RN 135839-22-4 CAPLUS
 CN SH-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)


<12/04/2007>

Erich Leese

<12/04/2007>

Erich Leese

CN SH-(1,3)Diazepino[2,1-i]purin-5-one, 3,4,7,8,9,10-hexahydro-3,4-dipropyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 39 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1996:432308 CAPLUS
 DOCUMENT NUMBER: 125:157747
 TITLE: Theoretical structure-activity studies of adenosine A1 ligands: requirements for receptor affinity
 AUTHOR(S): Dooley, Michael J.; Kono, Motomichi; Suzuki, Fumio
 CORPORATE SOURCE: Pharmaceutical Res. Lab., Kyowa Hakko Kogyo Co. Ltd., Shinjuku-ku, 430-0011, Japan
 SOURCE: Bioorganic & Medicinal Chemistry (1996), 4(6), 923-934
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The three-dimensional (3-D) requirements for A1 adenosine receptor affinity have been studied based on hydrogen-bonding functionality correlation between a group of twelve A1 adenosine receptor ligands representing ten structurally different classes of compds. Electrostatic potential similarity indexes and shape similarity indexes strongly support the proposed receptor-bound orientations of the ligands. We conclude, in areas common to both agonist and antagonist binding at the A1 receptor, that the ligands are recognized by a similar physicochem. 3-D environment. The finding of similar 3-D requirements for agonists and antagonists suggests a fairly static receptor structure in the region common to agonist and antagonist binding. The ribose moiety is remote from antagonist binding site. Such a 3-D environment rationalizes the binding of a number of potent novel antagonists including KN-3902, not previously reported in modeling studies.


IT 180145-17-9
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (theor. structure-activity studies of adenosine A1 ligands: requirements for receptor affinity)
 RN 180145-17-9 CAPLUS
 CN SH-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-4-propyl-2-tricyclo[3.3.1.13.7]dec-1-yl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 195869-73-9 CAPLUS
 CN SH-Imidazo[2,1-i]purin-5-one, 3,4,7,8-tetrahydro-3,4-dipropyl- (9CI) (CA INDEX NAME)



RN 195869-81-9 CAPLUS
 CN Pyrimido[2,1-i]purin-5(1H)-one, 4,7,8,9-tetrahydro-1,4-dipropyl- (9CI) (CA INDEX NAME)



RN 195869-95-5 CAPLUS
 CN Pyrimido[2,1-i]purin-5(3H)-one, 4,7,8,9-tetrahydro-3,4-dipropyl- (9CI) (CA INDEX NAME)




RN 195870-05-4 CAPLUS

<12/04/2007>

Erich Leese

<12/04/2007>

Erich Leese



L4 ANSWER 40 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1995:58989 CAPLUS
 DOCUMENT NUMBER: 123:74621
 TITLE: Effects of the adenosine A1-receptor antagonist on defecation, small intestinal propulsion and gastric emptying in rats
 AUTHOR(S): Suzuki, Mayumi; Tomaru, Atsushi; Kishibayashi, Nobuyuki; Karasawa, Akira
 CORPORATE SOURCE: Pharmaceut. Res. Lab., Kyowa Hakko Kogyo Co., Ltd., Shizuoka, 411, Japan
 SOURCE: Japanese Journal of Pharmacology (1995), 60(1), 110-23
 CODEN: JJPAAZ, ISSN: 0021-5198
 PUBLISHER: Japanese Pharmacological Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB We examined the effects of 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) and (R)-1,7-dihydro-8-ethyl-2-(3-noradamantyl)-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one (KF20274), selective adenosine A1-receptor antagonists, on the gastrointestinal propulsion in rats, as compared with those of the laxative bisacodyl. DPCPX and KF20274 (p.o.) dose-dependently increased the fecal pellet output, whereas these drugs at the dose that increased defecation did not affect small intestinal propulsion or gastric emptying. Bisacodyl increased defecation and slowed gastric emptying without any influence on small intestinal propulsion. Bisacodyl, but not DPCPX or KF20274, induced diarrhea at the dose inducing defecation. The present results suggest that the adenosine A1-receptor antagonist selectively enhances the lower gastrointestinal propulsion, resulting in defecation without diarrhea.

IT 143394-69-7 KF 20274
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (effects of adenosine A1-receptor antagonist on defecation, small intestinal propulsion and gastric emptying in rats)
 RN 143394-68-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-2-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1,4,7,8-tetrahydro-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese


L4 ANSWER 41 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1994:77080 CAPLUS
 DOCUMENT NUMBER: 120:77086
 TITLE: Convenient synthesis of tricyclic purine derivatives
 AUTHOR(S): Shimada, Junichi; Kuroda, Takeshi; Suzuki, Fumio
 CORPORATE SOURCE: Pharm. Res. Lab., Kyowa Hakko Kogyo Co., Ltd., Shizuoka, 411, Japan
 SOURCE: Journal of Heterocyclic Chemistry (1993), 30(1), 241-6
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 120:77080
 GI




AB A convenient synthesis of the title compds. I (R = H, cyclopentyl; n = 0-2) and II is described. The syntheses of I and II were accomplished by treatment of 6-methylthio-7H-purin-2(3H)-ones or 2-benzylthio-1-methyl-9-triphenylmethyl-9H-purin-6(1H)-one (III) with the appropriate amino alc. followed by dehydrative cyclization using SOCl2. III was efficiently prepared by benzylation of 6-hydroxy-2-mercaptopurine followed by tritylation and N-methylation.
 IT 135839-22-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and methylation of)
 RN 135839-22-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




IT 135839-21-3P 135839-26-8P 152036-10-7P
 152036-11-8P 152036-12-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 135839-21-3 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-1-methyl-4-propyl- (9CI) (CA INDEX NAME)



RN 135839-26-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)



RN 152036-12-9 CAPLUS
 CN Pyrimido[2,1-i]purin-5(1H)-one, 2-cyclopentyl-4,7,8,9-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)



L4 ANSWER 42 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1993:551642 CAPLUS
 DOCUMENT NUMBER: 119:151642
 TITLE: Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-(1-(R)-phenylisopropyl)adenosine-induced cognitive disturbance
 AUTHOR(S): Suzuki, Fumio; Shimada, Junichi; Shiozaki, Shizuo;

RN 152036-10-7 CAPLUS
 CN Pyrimido[2,1-i]purin-5(1H)-one, 2-cyclopentyl-4,7,8,9-tetrahydro-4-propyl-, monohydrochloride (9CI) (CA INDEX NAME)

<12/04/2007>


Erich Leese

<12/04/2007>

Erich Leese

10/513699

CORPORATE SOURCE: Ichikawa, Shunji; Ishii, Akio; Nakamura, Joji; Nonaka, Hiromi; Kobayashi, Hiroyuki; Puse, Eiichi
Pharm. Res. Lab., Kyowa Hakko Kogyo Co., Ltd., Nagizumi, 411, Japan
Journal of Medicinal Chemistry (1993), 36(17), 2508-18
CODEN: JMCMAR; ISSN: 0022-2633
DOCUMENT TYPE: Journal
LANGUAGE: English
01



AB The effects of a variety of adenosine A1 and A2 antagonists (I, R1 = e.g., Me or Pr; R2 = Me, Pr, or iso-Bu; R3 = H or Me; R4 = H, cyclopentyl, noradamantyl, or adamantlyl; X = O or S) on N6-(R)-phenylisopropyladenosine (R-PIA)- and scopolamine-induced amnesia were investigated in rodents to clarify the role of adenosine receptors in learning and memory. Some of the selective adenosine A1 antagonists exhibited antimnemonic activities at several doses where they did not induce an increase of spontaneous locomotion. The blockade of A1 receptors is more important than that of A2 receptors in learning and memory. Detailed studies of structure-activity relations of adenosine A1 antagonists in 2 amnesia models demonstrated that there were 3 types of adenosine A1 antagonists: 8-substituted 1,3-dipropylxanthines ameliorated the shortened latency in both models. 8-Substituted 1,3-dialkylxanthines and imidazo[2,1-i]purin-5(4H)-one derivs. ameliorated the shortened latency in the (R)-PIA-induced amnesia model but not in the scopolamine-induced amnesia model. I (R1 = Pr, R2 = CH2CH2C6H4NR, R = H, acetyl or isobutyryl, R3 = H, R4 = e.g., cyclopentyl or 3-noradamantyl, X = O) (II) ameliorated the shortened latency in the scopolamine model but not in the (R)-PIA model. II did not exhibit adenosine A1 antagonism in vivo probably due to rapid metabolism. The different stabilities of II could not be explained by their simple pharmacokinetic differences, because both types of compounds showed clear blockade of central adenosine A1 receptors in the (R)-PIA model. KF15372 (I, R1 = R2 = Pr; R3 = H; R4 = dicyclopropylmethyl; X = O) was chosen for further studies and is currently under preclin. development as a cognition enhancer.

IT 143394-68-7P 143394-70-1P 149744-78-5P

RL: 8PN (Synthetic preparation); PREP (Preparation)
(preparation and adenosine A1 and A2 receptor antagonist activities of, structure in relation to)

RN 143394-68-7 CAPLUS


CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-2-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1,4,7,8-tetrahydro-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

<12/04/2007>


Erich Leese

10/513699




RN 143394-70-1 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-2-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1,4,7,8-tetrahydro-4-propyl-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149744-78-5 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-2-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




IT 143394-69-8P 143394-71-2P
RL: 8PN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 143394-69-8 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-2-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1,4,7,8-tetrahydro-4-propyl-, (8R)- (9CI) (CA INDEX NAME)

<12/04/2007>

Erich Leese

10/513699

3a(1H)-yl)-1,4,7,8-tetrahydro-4-propyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 143394-69-8 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-2-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1,4,7,8-tetrahydro-4-propyl-, (8R), (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 143394-68-7
CMF C21 H29 NS O

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.

10/513699


OH
HO₂C R CO₂H
OH

RN 143394-71-2 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-2-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1,4,7,8-tetrahydro-4-propyl-, (8S), (8-(R*,R*))-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 143394-70-1
CMF C21 H29 NS O

Absolute stereochemistry.



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.

CM 2
CRN 147-71-7
CMF C4 H6 O6

L4 ANSWER 43 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:612210 CAPLUS
DOCUMENT NUMBER: 117:212210
TITLE: 7,8-Dihydro-8-ethyl-2-(3-noradamantyl)-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one: a potent and water-soluble adenosine A1 antagonist
AUTHOR(S): Suzuki, Fumio; Shimada, Junichi; Nonaka, Hiromi;


<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese

CORPORATE SOURCE: Ishii, Akio; Shiozaki, Shizuo; Ichikawa, Shunji; Omo, Sizichi
Pharm. Res. Lab., Kyowa Hakko Kogyo Co., Ltd., Nagaijumi, 41, Japan
SOURCE: Journal of Medicinal Chemistry (1992), 35(19), 3578-81
DOCUMENT TYPE: CODEN: JMCMAR; ISSN: 0022-2633
LANGUAGE: English
GI



AB A new tricyclic heterocycle, 7,8-dihydro-8-ethyl-2-(3-noradamantyl)-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one (I), exhibited a potent adenosine A₁ antagonistic activity in vitro and in vivo. This unique nonxanthine adenosine antagonist showed much better water solubility (3.2 mg/mL) than potent A₁ antagonists reported to date. Anal. of adenosine A₁ receptor binding of R- and S-I suggest a new receptor binding mode.
IT 143332-28-9P 143394-69-8P 143394-71-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, water solubility, and adenosine A₁ antagonistic activity of)
RN 143332-28-9 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-2-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1,4,7,8-tetrahydro-4-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 143394-69-8 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-2-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1,4,7,8-tetrahydro-4-propyl-, (R)-, (2R,3R)-2,3-

<12/04/2007>

Erich Leese

<12/04/2007>


Erich Leese

dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 143394-68-7
CMF C21 H29 NS O


Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 143394-71-2 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-2-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1,4,7,8-tetrahydro-4-propyl-, (S)-, (8-(R*,R*))-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 143394-70-1
CMF C21 H29 NS O

Absolute stereochemistry.

CM 2

CRN 143394-70-1


CMF C21 H29 NS O

Absolute stereochemistry.


PRIORITY APPLN. INFO.: JP 1989-273403 A 19891020
OTHER SOURCE(S): MARPAT 115:136115
GI For diagram(s), see printed CA Issue.
AB Title compds. I (A = O, Q, Q2) R = H, alkyl, alicyclic alkyl, noradamantyl, 3-ylidocyclopropylmethyl, styryl, R2 = H, alkyl, alicyclic alkyl, R3 = H, alkyl, PhCO2, Et, X3 = H, alkyl, aralkyl, Ph, n = 0, 1) or a salt thereof, useful as diuretics, renal protecting agents, bronchodilators or hypotensives, are prepared. Thus, H2CH2CH2OH was added to 3,7-dihydro-7-methyl-6-(methylthiol-3-propyl-2H-purin-2-one (preparation given) and treated at 160° for 1 h to give the hydroxyethylamino derivative which was refluxed with POC13 and after workup to give the imidazopurinone II. II showed biol. activity as the above agents. Pharmaceutical formulations are given.

IT 135839-21-3P 135839-22-4P 135839-23-5P
135839-24-6P 135839-25-7P 135839-26-8P
135839-27-9P 135839-28-0P 135839-29-1P
135839-30-4P 135839-31-5P 135839-32-6P
135839-33-7P 135839-34-8P 135839-35-9P
135839-36-0P 135839-37-1P 135839-38-2P
135839-39-3P 135839-40-6P 135839-41-7P
135839-42-8P 143332-28-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BPN (Synthetic preparation); ITH (Therapeutic Use); BIOL (Biological study); PRBP (Preparation); USES (Uses)
(preparation of, as drug)
RN 135839-21-3 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-1-methyl-4-propyl- (9CI) (CA INDEX NAME)



RN 135839-22-4 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)



RN 135839-23-5 CAPLUS
CN Pyrimido[2,1-i]purin-5(1H)-one, 4,7,8,9-tetrahydro-1-methyl-4-propyl- (9CI) (CA INDEX NAME)

I4 ANSWER 44 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1991:56115 CAPLUS
DOCUMENT NUMBER: 115:136115
TITLE: Preparation of condensed purine derivatives as drugs
INVENTOR(S): Suzuki, Fumio; Shimada, Junichi; Kuroda, Takeshi; Kubo, Kazuhiro; Karasawa, Akira; Ohno, Tetsuji; Ohmori, Kenji
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 43 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 423805	A2	19910424	EP 1990-120056	19901019
EP 423805	A3	19920102		
EP 423805	B1	20000823		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2028235	A1	19910421	CA 1990-2028235	19901019
CA 2028235	C	19970121		
JP 03204880	A	19910906	JP 1990-281578	19901019
US 5270316	A	19931214	US 1990-599758	19901019
AT 195739	T	20000915	AT 1990-120056	19901019
ES 2152207	T3	20010201	ES 1990-120056	19901019


<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese


10/513699




RN 135839-24-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-1-methyl-4-propyl- (9CI) (CA INDEX NAME)



RN 135839-25-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-1-methyl-7-phenyl-4-propyl- (9CI) (CA INDEX NAME)



RN 135839-26-8 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4-propyl- (9CI) (CA INDEX NAME)




<12/04/2007>


Erich Leese

10/513699

RN 135839-27-9 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-1-methyl-4-propyl- (9CI) (CA INDEX NAME)




RN 135839-28-0 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-8-ethyl-1,4,7,8-tetrahydro-4-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 135839-29-1 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-4-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 135839-30-4 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-1-methyl-4-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


10/513699

methylethyl)-4-propyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 135839-31-5 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-7-phenyl-4-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 135839-32-6 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(phenylmethyl)-4-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 135839-33-7 CAPLUS
 CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-(1-

<12/04/2007>


Erich Leese

<12/04/2007>

Erich Leese


10/513699

CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-8-methyl-4-propyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 135839-37-1 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-4,8-dipropyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 135839-38-2 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-7-ethyl-1,4,7,8-tetrahydro-4-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

<12/04/2007>


Erich Leese

<12/04/2007>

Erich Leese


10/513699

RN 135839-42-8 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 1,4,7,8-tetrahydro-7-phenyl-4-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 143332-28-9 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-2-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-1,4,7,8-tetrahydro-4-propyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 45 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1990:136984 CAPLUS
DOCUMENT NUMBER: 112:138984
TITLE: Synthesis of new heteroannulated 8-azapurines
AUTHOR(S): Ried, Walter; Laoutidis, Joannis
CORPORATE SOURCE: Inst. Org. Chem., Univ. Frankfurt, Frankfurt, D-6000/70, Germany
SOURCE: Liebigs Annalen der Chemie (1990), (2), 207-8
CODEN: LACHDL; ISSN: 0170-2041
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 112:138984
O1 For diagram(s), see printed CA issue.
AB The aminotriazoles I (R = H, 2-Cl, 4-Cl, 2,4-Cl2) reacted with XCR12 (X =


10/513699

RN 135839-39-3 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-cyclopentyl-1,4,7,8-tetrahydro-7-methyl-4-propyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 135839-40-6 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 2-(dicyclopropylmethyl)-8-ethyl-1,4,7,8-tetrahydro-4-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 135839-41-7 CAPLUS
CN 5H-Imidazo[2,1-i]purin-5-one, 8-ethyl-1,4,7,8-tetrahydro-1-methyl-2-(2-phenylethyl)-4-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese


10/513699

O, R = Cl, R1 = Cl, OPh; X = K, R1 = R2 = Cl; X = C(CN)2, NCN, R1 = R2 = SMe) to give the title compds. II.
IT 124127-56-6P 124127-57-7P 124127-58-8P
124127-59-9P
RL: BPN (Synthetic preparation); PREP (Preparation)
Iridation of


RN 124127-56-6 CAPLUS
CN Pyrimidolo[1,2-c]-1,2,3-triazolo[4,5-e]pyrimidin-5(3H)-one,
3-((2-chlorophenyl)methyl)-4,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 124127-57-7 CAPLUS
CN Pyrimidolo[1,2-c]-1,2,3-triazolo[4,5-e]pyrimidin-5(3H)-one,
3-((4-chlorophenyl)methyl)-4,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 124127-58-8 CAPLUS
CN Pyrimidolo[1,2-c]-1,2,3-triazolo[4,5-e]pyrimidin-5(3H)-one,
3-((2,4-dichlorophenyl)methyl)-4,7,8,9-tetrahydro- (9CI) (CA INDEX NAME)



RN 124127-59-9 CAPLUS
CN Pyrimidolo[1,2-c]-1,2,3-triazolo[4,5-e]pyrimidin-5(3H)-one,
4,7,8,9-tetrahydro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)


<12/04/2007>

Erich Leese


<12/04/2007>

Erich Leese


10/513699



10/513699



LA ANSWER 46 OF 46 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1980:579371 CAPLUS
 DOCUMENT NUMBER: 93:179371
 TITLE: Substituted 6,7-dihydroimidazo[1,2-al]purin-9(4H)-ones
 AUTHOR(S): Temple, D. L., Jr.; Yevich, J. P.; Catt, J. D.; Owens, D.; Hanning, C.; Covington, R. R.; Seidehamel, R. J.; Dungan, K. W.
 CORPORATE SOURCE: R&D Lab., Mead Johnson Pharm., Evansville, IN, 47721, USA
 SOURCE: Journal of Medicinal Chemistry (1980), 23(11), 1180-98
 CODEN: JMCMAR, ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 93:179371
 GI:



I

AB The title compds., mostly represented by I (R1 and R4 = H or alkyl; R2 = H, Br, Alkyl, Ph, SH, or Mes; R3 = alkyl, benzyl, or substituted benzyl; R5 = H or alkyl, X = O or S), were prepared by several methods and evaluated in rats for antiallergic and bronchodilator activities. 4-[(4-Chlorophenyl)methyl]-6,7-dihydro-3H-imidazo[1,2-al]purin-9(4H)-one [68020-42-8] showed better activity than theophylline against both metacholine- and antigen-induced bronchospasm, did not affect spontaneous motor activity, and showed minimal cardiovascular effects. Structure-activity relations are discussed.

IT 75185-17-0
 RL: SPN (Synthetic preparation); PREP.(Preparation)
 (preparation and antiallergic and bronchodilator activity of)
 RN 75185-17-0 CAPLUS
 CN SH-Imidazo[2,1-i]purin-5-one, 4-[(4-chlorophenyl)methyl]-1;4,7,8-tetrahydro- (9CI) (CA INDEX NAME)

<12/04/2007>

Erich Leese

<12/04/2007>

Erich Leese